U.S. patent application number 13/519518 was filed with the patent office on 2012-11-15 for treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3).
This patent application is currently assigned to CuRNA, Inc.. Invention is credited to Joseph Collard, Olga Khorkova Sherman.
Application Number | 20120289583 13/519518 |
Document ID | / |
Family ID | 44227151 |
Filed Date | 2012-11-15 |
United States Patent
Application |
20120289583 |
Kind Code |
A1 |
Collard; Joseph ; et
al. |
November 15, 2012 |
TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES
BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND
TRANSCRIPTION FACTOR E3 (TFE3)
Abstract
The present invention relates to antisense oligonucleotides that
modulate the expression of and/or function of Insulin Receptor
Substrate 2 (IRS2) polynucleotides, in particular, by targeting
natural antisense polynucleotides of Insulin Receptor Substrate 2
(IRS2) polynucleotides and Transcription factor E3 (TFE3). The
invention also relates to the identification of these antisense
oligonucleotides and their use in treating diseases and disorders
associated with the expression of IRS2.
Inventors: |
Collard; Joseph; (Delray
Beach, FL) ; Khorkova Sherman; Olga; (Tequesta,
FL) |
Assignee: |
CuRNA, Inc.
Miami
FL
|
Family ID: |
44227151 |
Appl. No.: |
13/519518 |
Filed: |
December 30, 2010 |
PCT Filed: |
December 30, 2010 |
PCT NO: |
PCT/US10/62463 |
371 Date: |
June 27, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61291419 |
Dec 31, 2009 |
|
|
|
Current U.S.
Class: |
514/44A ;
435/375; 436/501; 536/24.5 |
Current CPC
Class: |
C12N 2310/11 20130101;
A61P 43/00 20180101; C12N 2310/321 20130101; C12N 2310/113
20130101; C12N 2310/314 20130101; A61P 3/08 20180101; C12N 15/113
20130101; C12N 2310/315 20130101; A61K 31/711 20130101; A61P 3/04
20180101; A61P 1/16 20180101; A61P 3/10 20180101; C12N 2310/312
20130101; C12N 2310/32 20130101; A61P 13/12 20180101; C12N
2310/3181 20130101; A61P 21/00 20180101; A61P 25/16 20180101; A61P
25/00 20180101; C12N 2310/322 20130101; A61P 25/28 20180101; C12N
2310/313 20130101; A61P 21/02 20180101; A61P 35/00 20180101; C12N
2310/316 20130101; C12N 2310/17 20130101; A61P 3/00 20180101; A61P
15/00 20180101; A61P 9/10 20180101; C12N 2310/3231 20130101 |
Class at
Publication: |
514/44.A ;
435/375; 536/24.5; 436/501 |
International
Class: |
A61K 31/7088 20060101
A61K031/7088; A61K 31/7115 20060101 A61K031/7115; A61K 31/712
20060101 A61K031/712; A61K 31/7125 20060101 A61K031/7125; A61K
31/711 20060101 A61K031/711; A61K 31/713 20060101 A61K031/713; C07H
21/00 20060101 C07H021/00; C07H 21/04 20060101 C07H021/04; A61P
3/10 20060101 A61P003/10; A61P 3/04 20060101 A61P003/04; A61P 3/08
20060101 A61P003/08; A61P 3/00 20060101 A61P003/00; A61P 15/00
20060101 A61P015/00; A61P 9/10 20060101 A61P009/10; A61P 35/00
20060101 A61P035/00; A61P 25/28 20060101 A61P025/28; A61P 25/16
20060101 A61P025/16; G01N 21/64 20060101 G01N021/64; C12N 5/071
20100101 C12N005/071 |
Claims
1. A method of modulating a function of and/or the expression of a
Insulin Receptor Substrate 2 (IRS2) polynucleotide in patient cells
or tissues in vivo or in vitro comprising: contacting said cells or
tissues with at least one antisense oligonucleotide 5 to 30
nucleotides in length wherein said at least one oligonucleotide has
at least 50% sequence identity to a reverse complement of a
polynucleotide comprising 5 to 30 nucleotides within nucleotides: 1
to 497 of SEQ ID NO: 2 or nucleotides 1 to 633 of SEQ ID NO: 3;
thereby modulating a function of and/or the expression of the
Insulin Receptor Substrate 2 (IRS2) polynucleotide in patient cells
or tissues in vivo or in vitro.
2. A method of modulating a function of and/or the expression of a
Insulin Receptor Substrate 2 (IRS2) polynucleotide in patient cells
or tissues in vivo or in vitro comprising: contacting said cells or
tissues with at least one antisense oligonucleotide 5 to 30
nucleotides in length wherein said at least one oligonucleotide has
at least 50% sequence identity to a reverse complement of a natural
antisense of a Transcription factor E3 (TFE3) polynucleotide or
Insulin Receptor Substrate 2 (IRS2); thereby modulating a function
of and/or the expression of the Insulin Receptor Substrate 2 (IRS2)
polynucleotide in patient cells or tissues vivo or in vitro.
3. A method of modulating a function of and/or the expression of a
Insulin Receptor Substrate 2 (IRS2) polynucleotide patient cells or
tissues in vivo or in vitro comprising: contacting said cells or
tissues with at least one antisense oligonucleotide 5 to 30
nucleotides in length wherein said oligonucleotide has at least 50%
sequence identity to an antisense oligonucleotide to the
Transcription factor E3 (TFE3) polynucleotide or Insulin Receptor
Substrate 2 (IRS2); thereby modulating a function of and/or the
expression of the Insulin Receptor Substrate 2 (IRS2)
polynucleotide in patient cells or tissues in vivo or in vitro.
4. A method of modulating a function of and/or the expression of a
Receptor Substrate 2 (IRS2) polynucleotide in patient cells or
tissues in vivo or in vitro comprising: contacting said cells or
tissues with at least one antisense oligonucleotide that targets a
region of a natural antisense oligonucleotide of the Transcription
factor E3 (TFE3) or insulin Receptor Substrate 2 (IRS2)
polynucleotide; thereby modulating a function of and/or the
expression of the Insulin Receptor Substrate 2 (IRS2)
polynucleotide in patient cells or tissues in vivo or in vitro.
5. The method of claim 4, wherein a function of and/or the
expression of the Insulin Receptor Substrate 2 (IRS2) is increased
in vivo or in vitro with respect to a control.
6. The method of claim 4, wherein the at least one antisense
oligonucleotide targets a natural antisense sequence of a
Transcription factor E3 (TFE3) polynucleotide or Insulin Receptor
Substrate 2 (IRS2).
7. The method of claim 4, wherein the at least one antisense
oligonucleotide targets a nucleic acid sequence comprising coding
and/or non-coding nucleic acid sequences of a Transcription factor
E3 (TFE3) or Insulin Receptor Substrate 2 (IRS2)
polynucleotide.
8. The method of claim 4, wherein the at least one antisense
oligonucleotide targets overlapping and/or non-overlapping
sequences of a Transcription factor E3 (TFE3) or Insulin Receptor
Substrate 2 (IRS2) polynucleotide.
9. The method of claim 4, wherein the at least one antisense
oligonucleotide comprises one or more modifications selected from:
at least one modified sugar moiety, at least one modified
internucleoside linkage, at least one modified nucleotide, and
combinations thereof.
10. The method of claim 9, wherein the one or more modifications
comprise at least one modified sugar moiety selected from: a
2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified
sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar
moiety, and combinations thereof.
11. The method of claim 9, wherein the one or more modifications
comprise at least one modified internucleoside linkage selected
from: a phosphorothioate, 2'-Omethoxyethyl (MOE), 2'-fluoro,
alkylphosphonate, phosphorodithioate, alkylphosphonothioate,
phosphoramidate, carbamate, carbonate, phosphate triester,
acetamidate, carboxymethyl ester, and combinations thereof.
12. The method of claim 9, wherein the one or more modifications
comprise at least one modified nucleotide selected from: a peptide
nucleic acid (PNA), a locked nucleic acid (LNA), an arabino-nucleic
acid (FANA), an analogue, a derivative, and combinations
thereof.
13. The method of claim 1, wherein the at least one oligonucleotide
comprises at least one oligonucleotide sequences set forth as SEQ
ID NOS: 4 to 9.
14. A method of modulating a function of and/or the expression of a
Insulin Receptor Substrate 2 (IRS2) gene in mammalian cells or
tissues in vivo or in vitro comprising: contacting said cells or
tissues with at least one short interfering RNA (siRNA)
oligonucleotide 5 to 30 nucleotides in length, said at least one
siRNA oligonucleotide being specific for an antisense
polynucleotide of a Transcription factor E3 (TFE3) or Insulin
Receptor Substrate 2 (IRS2) polynucleotide, wherein said at least
one siRNA oligonucleotide has at least 50% sequence identity to a
complementary sequence of at least about five consecutive nucleic
acids of the antisense and/or sense nucleic acid molecule of the
Transcription factor E3 (TFE3) or Insulin Receptor Substrate 2
(IRS2) polynucleotide; and, modulating a function of and/or the
expression of or Insulin Receptor Substrate 2 (IRS2) in mammalian
cells or tissues in vivo or in vitro.
15. The method of claim 14, wherein said oligonucleotide has at
least 80% sequence identity to a sequence of at least about five
consecutive nucleic acids that is complementary to the antisense
and/or sense nucleic acid molecule of the Transcription factor
E3(TFE3) or Insulin Receptor Substrate 2 (IRS2) polynucleotide.
16. A method of modulating a function of and/or the expression of
Insulin Receptor Substrate 2 (IRS2) in mammalian cells or tissues
in vivo or in vitro comprising: contacting said cells or tissues
with at least one antisense oligonucleotide of about 5 to 30
nucleotides in length specific for noncoding and/or coding
sequences of a sense and/or natural antisense strand of a
Transcription factor E3 (TFE3) or Insulin Receptor Substrate 2
(IRS2) polynucleotide wherein said at least one antisense
oligonucleotide has at least 50% sequence identity to at least one
nucleic acid sequence set forth as SEQ ID NOS: 1 to 3; and,
modulating the function and/or expression of the Insulin Receptor
Substrate 2 (IRS2) in mammalian cells or tissues in vivo or in
vitro.
17. A synthetic, modified oligonucleotide comprising at least one
modification wherein the at least one modification is selected
from: at least one modified sugar moiety; at least one modified
internucleotide linkage; at least one modified nucleotide, and
combinations thereof; wherein said oligonucleotide is an antisense
compound which hybridizes to and modulates the function and/or
expression of a Insulin Receptor Substrate 2 (IRS2) gene in vivo or
in vitro as compared to a normal control.
18. The oligonucleotide of claim 17, wherein the at least one
modification comprises an internucleotide linkage selected from the
group consisting of phosphorothioate, alkylphosphonate,
phosphorodithioate, alkylphosphonothioate, phosphoramidate,
carbamate, carbonate, phosphate triester, acetamidate,
carboxymethyl ester, and combinations thereof.
19. The oligonucleotide of claim 17, wherein said oligonucleotide
comprises at least one phosphorothioate internucleotide
linkage.
20. The oligonucleotide of claim 17, wherein said oligonucleotide
comprising a backbone of phosphorothioate internucleotide
linkages.
21. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises at least one modified nucleotide, said modified
nucleotide selected from: a peptide nucleic acid, a locked nucleic
acid (LNA), analogue, derivative, and a combination thereof.
22. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises a plurality of modifications, wherein said modifications
comprise modified nucleotides selected from: phosphorothioate,
alkylphosphonate, phosphorodithioate, alkylphosphonothioate,
phosphoramidate, carbamate, carbonate, phosphate triester,
acetamidate, carboxymethyl ester, and a combination thereof.
23. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises a plurality of modifications, wherein said modifications
comprise modified nucleotides selected from: peptide nucleic acids,
locked nucleic acids (LNA), analogues, derivatives, and a
combination thereof.
24. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises at least one modified sugar moiety selected from: a
2'-O-methoxyethyl modified sugar moiety, a 2'-methoxy modified
sugar moiety, a 2'-O-alkyl modified sugar moiety, a bicyclic sugar
moiety, and a combination thereof.
25. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises a plurality of modifications, wherein said modifications
comprise modified sugar moieties selected from: a 2'-O-methoxyethyl
modified sugar moiety, a 2'-methoxy modified sugar moiety, a
2'-O-alkyl modified sugar moiety, a bicyclic sugar moiety, and a
combination thereof.
26. The oligonucleotide of claim 17, wherein the oligonucleotide is
of at least about 5 to 30 nucleotides in length and hybridizes to
an antisense and/or sense strand of a Transcription factor E3
(TFE3) or Insulin Receptor Substrate 2 (IRS2) wherein said
oligonucleotide has at least about 20% sequence identity to a
complementary sequence of at least about five consecutive nucleic
acids of the antisense and/or sense coding and/or noncoding nucleic
acid sequences of the Transcription factor E3 (TFE3) or Insulin
Receptor Substrate 2 (IRS2) polynucleotide.
27. The oligonucleotide of claim 17, wherein the oligonucleotide
has at least about 80% sequence identity to a complementary
sequence of at least about five consecutive nucleic acids of the
antisense and/or sense coding and/or noncoding nucleic acid
sequence of the Transcription factor E3 (TFE3) or Insulin Receptor
Substrate 2 (IRS2) polynucleotide.
28. The oligonucleotide of claim 17, wherein said oligonucleotide
hybridizes to and modulates expression and/or function of at least
one insulin Receptor Substrate 2 (IRS2) polynucleotide in vivo or
in vitro, as compared to a normal control.
29. The oligonucleotide of claim 17, wherein the oligonucleotide
comprises the sequences set forth as SEQ ID NOS: 4 to 9.
30. A composition comprising one or more oligonucleotides specific
for one or more Transcription factor E3 (TFE3) or Insulin Receptor
Substrate 2 (IRS2) polynucleotides, said polynucleotides comprising
antisense sequences, complementary sequences, alleles, homologs,
isoforms, variants, derivatives, mutants, fragments, or
combinations thereof.
31. The composition of claim 30, wherein the oligonucleotides have
at least about 40% sequence identity as compared to any one of the
nucleotide sequences set forth as SEQ ID NOS: 4 to 9.
32. The composition of claim 30, wherein the oligonucleotides
comprise nucleotide sequences set forth as SEQ ID NOS: 4 to 9.
33. The composition of claim 32, wherein the oligonucleotides set
forth as SEQ ID NOS: 4 to 9 comprise one or more modifications or
substitutions.
34. The composition of claim 33, wherein the one or more
modifications are selected from: phosphorothioate,
methylphosphonate, peptide nucleic acid, locked nucleic acid (LNA)
molecules, and combinations thereof.
35. A method of preventing or treating a disease associated with at
least one Insulin Receptor Substrate 2 (IRS2) polynucleotide and/or
at least one encoded product thereof, comprising: administering to
a patient a therapeutically effective dose of at least one
antisense oligonucleotide that binds to a natural antisense
sequence of said at least one Transcription factor E3 (TFE3) or
Insulin Receptor Substrate 2 (IRS2) polynucleotide and modulates
expression of said at least one Insulin Receptor Substrate 2 (IRS2)
polynucleotide; thereby preventing or treating the disease
associated with the at least one Insulin Receptor Substrate 2
(IRS2) polynucleotide and/or at least one encoded product
thereof.
36. The method of claim 35, wherein a disease associated with the
at least one Insulin Receptor Substrate 2 (IRS2) polynucleotide is
selected from: a disease or disorder associated with abnormal
function and/or expression of IRS2 and/or TFE3, a neurological
disease or disorder (e.g. Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis etc.), a disease or disorder
associated with insulin resistance, diabetes, an insulin resistant
non diabetic state (e.g., obesity, impaired glucose tolerance
(IGT), Metabolic Syndrome etc.), a hepatic disease or disorder, a
disease or disorder associated with kidney growth and development,
a disease or disorder associated with skeletal muscle growth and/or
metabolism, a disease or disorder associated with carbohydrate
metabolism, a weight disorder, Polycystic Ovary Syndrome,
atherosclerosis, cancer, a disease or disorder associated with
apoptosis, a disease or disorder associated with aging and
senescence.
37. A method of identifying and selecting at least one
oligonucleotide for in vivo administration comprising: selecting a
target polynucleotide associated with a disease state; identifying
at least one oligonucleotide comprising at least five consecutive
nucleotides which are complementary to the selected target
polynucleotide or to a polynucleotide that is antisense to the
selected target polynucleotide; measuring the thermal melting point
of a hybrid of an antisense oligonucleotide and the target
polynucleotide or the polynucleotide that is antisense to the
selected target polynucleotide under stringent hybridization
conditions; and selecting at least one oligonucleotide for in vivo
administration based on the information obtained.
Description
[0001] The present application claims the priority of U.S.
provisional patent application No. 61/291,419 filed Dec. 31, 2009
which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
[0002] Embodiments of the invention comprise oligonucleotides
modulating expression and/or function of IRS2 and associated
molecules.
BACKGROUND
[0003] DNA-RNA and RNA-RNA hybridization are important to many
aspects of nucleic acid function including DNA replication,
transcription, and translation. Hybridization is also central to a
variety of technologies that either detect a particular nucleic
acid or alter its expression. Antisense nucleotides, for example,
disrupt gene expression by hybridizing to target RNA, thereby
interfering with RNA splicing, transcription, translation, and
replication. Antisense DNA has the added feature that DNA-RNA
hybrids serve as a substrate for digestion by ribonuclease H, an
activity that is present in most cell types. Antisense molecules
can be delivered into cells, as is the case for
oligodeoxynucleotides (ODNs), or they can be expressed from
endogenous genes as RNA molecules. The FDA recently approved an
antisense drug, VITRAVENE.TM. (for treatment of cytomegalovirus
retinitis), reflecting that antisense has therapeutic utility.
SUMMARY
[0004] This Summary is provided to present a summary of the
invention to briefly indicate the nature and substance of the
invention. It is submitted with the understanding that it will not
be used to interpret or limit the scope or meaning of the
claims.
[0005] In one embodiment, the invention provides methods for
inhibiting the action of a natural antisense transcript by using
antisense oligonucleotide(s) targeted to any region of the natural
antisense transcript resulting in up-regulation of the
corresponding sense gene. It is also contemplated herein that
inhibition of the natural antisense transcript can be achieved by
siRNA, ribozymes and small molecules, which are considered to be
within the scope of the present invention.
[0006] One embodiment provides a method of modulating function
and/or expression of an IRS2 polynucleotide in patient cells or
tissues in vivo or in vitro comprising contacting said cells or
tissues with an antisense oligonucleotide 5 to 30 nucleotides in
length wherein said oligonucleotide has at least 50% sequence
identity to a reverse complement of a polynucleotide comprising 5
to 30 consecutive nucleotides within nucleotides 1 to 497 of SEQ ID
NO: 2 or nucleotides 1 to 633 of SEQ ID NO: 3 thereby modulating
function and/or expression of the IRS2 polynucleotide in patient
cells or tissues in vivo or in vitro.
[0007] In an embodiment, an oligonucleotide targets a natural
antisense sequence of IRS2 or TFE3 polynucleotides, for example,
nucleotides set forth in SEQ ID NOS: 2 and 3, and any variants,
alleles, homologs, mutants, derivatives, fragments and
complementary sequences thereto. Examples of antisense
oligonucleotides are set forth as SEQ ID NOS: 4 to 9.
[0008] Another embodiment provides a method of modulating function
and/or expression of an IRS2 polynucleotide in patient cells or
tissues in vivo or in vitro comprising contacting said cells or
tissues with an antisense oligonucleotide 5 to 30 nucleotides in
length wherein said oligonucleotide has at least 50% sequence
identity to a reverse complement of the an antisense of the IRS2 or
TFE3 polynucleotide; thereby modulating function and/or expression
of the IRS2 polynucleotide in patient cells or tissues in vivo or
in vitro.
[0009] Another embodiment provides a method of modulating function
and/or expression of an IRS2 polynucleotide in patient cells or
tissues in vivo or in vitro comprising contacting said cells or
tissues with an antisense oligonucleotide 5 to 30 nucleotides in
length wherein said oligonucleotide has at least 50% sequence
identity to an antisense oligonucleotide to an IRS2 or TFE3
antisense polynucleotide; thereby modulating function and/or
expression of the IRS2 polynucleotide in patient cells or tissues
in vivo or in vitro.
[0010] In an embodiment, a composition comprises one or more
antisense oligonucleotides which bind to sense and/or antisense
IRS2 or TFE3 polynucleotides.
[0011] In an embodiment, the oligonucleotides comprise one or more
modified or substituted nucleotides.
[0012] In an embodiment, the oligonucleotides comprise one or more
modified bonds.
[0013] In yet another embodiment, the modified nucleotides comprise
modified bases comprising phosphorothioate, methylphosphonate,
peptide nucleic acids, 2'-O-methyl, fluoro- or carbon, methylene or
other locked nucleic acid (LNA) molecules. Preferably, the modified
nucleotides are locked nucleic acid molecules, including
.alpha.-L-LNA.
[0014] In an embodiment, the oligonucleotides are administered to a
patient subcutaneously, intramuscularly, intravenously or
intraperitoneally.
[0015] In an embodiment, the oligonucleotides are administered in a
pharmaceutical composition. A treatment regimen comprises
administering the antisense compounds at least once to patient;
however, this treatment can be modified to include multiple doses
over a period of time. The treatment can be combined with one or
more other types of therapies.
[0016] In an embodiment, the oligonucleotides are encapsulated in a
liposome or attached to a carrier molecule (e.g. cholesterol, TAT
peptide).
[0017] Other aspects are described infra.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] FIG. 1 is a graph of real time PCR results showing the fold
change+standard deviation in IRS2 mRNA after treatment of HepG2
cells and 518A2 cells with phosphorothioate oligonucleotides
introduced using Lipofectamine 2000, as compared to control. Bars
denoted as 518A2 CUR-0603, 518A2 CUR-0605 correspond to 518A2
cells' samples treated with SEQ ID NOS 4 and 5, respectively. And
Bars denoted as HepG2 CUR-0603, HepG2 CUR-0605, correspond to HepG2
cells' samples treated with SEQ ID NOS 4 and 5, respectively.
[0019] FIG. 2 is a graph of real time PCR results showing the fold
change+standard deviation in IRS2 mRNA after treatment of Vero76
cells with phosphorothioate oligonucleotides introduced using
Lipofectamine 2000, as compared to control. Bars denoted as
CUR-0690, CUR-0691, and CUR-0692 correspond to SEQ ID NOS 6, 7, and
8.
[0020] FIG. 3 is a graph of real time PCR results showing the fold
change+standard deviation in IRS2 mRNA after treatment of MCF7
cells with phosphorothioate oligonucleotides introduced using
Lipofectamine 2000, as compared to control. Bars denoted as
CUR-0690, CUR-0691, CUR-0692, and CUR-0693 correspond to SEQ ID NOS
6, 7, 8 and 9.
[0021] FIG. 4 is a graph of real time PCR results showing the fold
change+standard deviation in TFE3 mRNA after treatment of HepG2
cells with phosphorothioate oligonucleotides introduced using
Lipofectamine 2000, as compared to control. Bars denoted as
CUR-0603 and CUR-0605 correspond to SEQ ID NOS 4 and 5
respectively.
[0022] Sequence Listing Description--SEQ ID NO: 1: Homo sapiens
insulin receptor substrate 2 (IRS2), mRNA. (NCBI Accession No.:
NM.sub.--003749); SEQ ID NO: 2: Natural TFE3 antisense sequence
Hs.708291; SEQ ID NO: 3: Natural IRS2 antisense sequence Hs.
664616; SEQ ID NOs: 4 to 9: Antisense oligonucleotides; SEQ ID NOs:
10 and 11: Reverse complement sequences of the antisense
oligonucleotide SEQ ID NOS: 4 and 5 respectively. * indicates
phosphothioate bond and `r` indicates RNA.
DETAILED DESCRIPTION
[0023] Several aspects of the invention are described below with
reference to example applications for illustration. It should be
understood that numerous specific details, relationships, and
methods are set forth to provide a full understanding of the
invention. One having ordinary skill in the relevant art, however,
will readily recognize that the invention can be practiced without
one or more of the specific details or with other methods. The
present invention is not limited by the ordering of acts or events,
as some acts may occur in different orders and/or concurrently with
other acts or events. Furthermore, not all illustrated acts or
events are required to implement a methodology in accordance with
the present invention.
[0024] All genes, gene names, and gene products disclosed herein
are intended to correspond homologs from any species for which the
compositions and methods disclosed herein are applicable. Thus, the
terms include, but are not limited to genes and gene products from
humans and mice. It is understood that when a gene or gene product
from a particular species is disclosed, this disclosure is intended
to be exemplary only, and is not to be interpreted as a limitation
unless the context in which it appears clearly indicates. Thus, for
example, for the genes disclosed herein, which in some embodiments
relate to mammalian nucleic acid and amino acid sequences are
intended to encompass homologous and/or orthologous genes and gene
products from other animals including, but not limited to other
mammals, fish, amphibians, reptiles, and birds. In an embodiment,
the genes or nucleic acid sequences are human.
Definitions
[0025] The terminology used herein is for the purpose of describing
particular embodiments only and is not intended to be limiting of
the invention. As used herein, the singular forms "a", "an" and
"the" are intended to include the plural forms as well, unless the
context clearly indicates otherwise. Furthermore, to the extent
that the terms "including", "includes", "having", "has", "with", or
variants thereof are used in either the detailed description and/or
the claims, such terms are intended to be inclusive in a manner
similar to the term "comprising."
[0026] The term "about" or "approximately" means within an
acceptable error range for the particular value as determined by
one of ordinary skill in the art, which will depend in part on how
the value is measured or determined, i.e., the limitations of the
measurement system. For example, "about" can mean within 1 or more
than 1 standard deviation, per the practice in the art.
Alternatively, "about" can mean a range of up to 20%, preferably up
to 10%, more preferably up to 5%, and more preferably still up to
1% of a given value. Alternatively, particularly with respect to
biological systems or processes, the term can mean within an order
of magnitude, preferably within 5-fold, and more preferably within
2-fold, of a value. Where particular values are described in the
application and claims, unless otherwise stated the term "about"
meaning within an acceptable error range for the particular value
should be assumed.
[0027] As used herein, the term "mRNA" means the presently known
mRNA transcript(s) of a targeted gene, and any further transcripts
which may be elucidated.
[0028] By "antisense oligonucleotides" or "antisense compound" is
meant an RNA or DNA molecule that binds to another RNA or DNA
(target RNA, DNA). For example, if it is an RNA oligonucleotide it
binds to another RNA target by means of RNA-RNA interactions and
alters the activity of the target RNA. An antisense oligonucleotide
can upregulate or downregulate expression and/or function of a
particular polynucleotide. The definition is meant to include any
foreign RNA or DNA molecule which is useful from a therapeutic,
diagnostic, or other viewpoint. Such molecules include, for
example, antisense RNA or DNA molecules, interference RNA (RNAi),
micro RNA, decoy RNA molecules, siRNA, enzymatic RNA, therapeutic
editing RNA and agonist and antagonist RNA, antisense oligomeric
compounds, antisense oligonucleotides, external guide sequence
(EGS) oligonucleotides, alternate splicers, primers, probes, and
other oligomeric compounds that hybridize to at least a portion of
the target nucleic acid. As such, these compounds may be introduced
in the form of single-stranded, double-stranded, partially
single-stranded, or circular oligomeric compounds.
[0029] In the context of this invention, the term "oligonucleotide"
refers to an oligomer or polymer of ribonucleic acid (RNA) or
deoxyribonucleic acid (DNA) or mimetics thereof. The term
"oligonucleotide", also includes linear or circular oligomers of
natural and/or modified monomers or linkages, including
deoxyribonucleosides, ribonucleosides, substituted and
alpha-anomeric forms thereof, peptide nucleic acids (PNA), locked
nucleic acids (LNA), phosphorothioate, methylphosphonate, and the
like. Oligonucleotides are capable of specifically binding to a
target polynucleotide by way of a regular pattern of
monomer-to-monomer interactions, such as Watson-Crick type of base
pairing, Hoogsteen or reverse Hoogsteen types of base pairing, or
the like.
[0030] The oligonucleotide may be "chimeric", that is, composed of
different regions. In the context of this invention "chimeric"
compounds are oligonucleotides, which contain two or more chemical
regions, for example, DNA region(s), RNA region(s), PNA region(s)
etc. Each chemical region is made up of at least one monomer unit,
i.e., a nucleotide in the case of an oligonucleotides compound.
These oligonucleotides typically comprise at least one region
wherein the oligonucleotide is modified in order to exhibit one or
more desired properties. The desired properties of the
oligonucleotide include, but are not limited, for example, to
increased resistance to nuclease degradation, increased cellular
uptake, and/or increased binding affinity for the target nucleic
acid. Different regions of the oligonucleotide may therefore have
different properties. The chimeric oligonucleotides of the present
invention can be formed as mixed structures of two or more
oligonucleotides, modified oligonucleotides, oligonucleosides
and/or oligonucleotide analogs as described above.
[0031] The oligonucleotide can be composed of regions that can be
linked in "register", that is, when the monomers are linked
consecutively, as in native DNA, or linked via spacers. The spacers
are intended to constitute a covalent "bridge" between the regions
and have in preferred cases a length not exceeding about 100 carbon
atoms. The spacers may carry different functionalities, for
example, having positive or negative charge, carry special nucleic
acid binding properties (intercalators, groove binders, toxins,
fluorophors etc.), being lipophilic, inducing special secondary
structures like, for example, alanine containing peptides that
induce alpha-helices.
[0032] As used herein "IRS2" and "Insulin Receptor Substrate 2" are
inclusive of all family members, mutants, alleles, fragments,
species, coding and noncoding sequences, sense and antisense
polynucleotide strands, etc.
[0033] As used herein "TFE3" and "Transcription factor E3" are
inclusive of all family members, mutants, alleles, fragments,
species, coding and noncoding sequences, sense and antisense
polynucleotide strands, etc.
[0034] As used herein, the words Insulin Receptor Substrate 2,
Insulin Receptor Substrate-2, IRS-2 and IRS2, are considered the
same in the literature and are used interchangeably in the present
application.
[0035] As used herein, the words transcription factor E3, TFE3,
TFE-3, RCCP2 and TFEA, are considered the same in the literature
and are used interchangeably in the present application.
[0036] As used herein, the term "oligonucleotide specific for" or
"oligonucleotide which targets" refers to an oligonucleotide having
a sequence (i) capable of forming a stable complex with a portion
of the targeted gene, or (ii) capable of forming a stable duplex
with a portion of a mRNA transcript of the targeted gene. Stability
of the complexes and duplexes can be determined by theoretical
calculations and/or in vitro assays. Exemplary assays for
determining stability of hybridization complexes and duplexes are
described in the Examples below.
[0037] As used herein, the term "target nucleic acid" encompasses
DNA, RNA (comprising premRNA and mRNA) transcribed from such DNA,
and also cDNA derived from such RNA, coding, noncoding sequences,
sense or antisense polynucleotides. The specific hybridization of
an oligomeric compound with its target nucleic acid interferes with
the normal function of the nucleic acid. This modulation of
function of a target nucleic acid by compounds, which specifically
hybridize to it, is generally referred to as "antisense". The
functions of DNA to be interfered include, for example, replication
and transcription. The functions of RNA to be interfered, include
all vital functions such as, for example, translocation of the RNA
to the site of protein translation, translation of protein from the
RNA, splicing of the RNA to yield one or more mRNA species, and
catalytic activity which may be engaged in or facilitated by the
RNA. The overall effect of such interference with target nucleic
acid function is modulation of the expression of an encoded product
or oligonucleotides.
[0038] RNA interference "RNAi" is mediated by double stranded RNA
(dsRNA) molecules that have sequence-specific homology to their
"target" nucleic acid sequences. In certain embodiments of the
present invention, the mediators are 5-25 nucleotide "small
interfering" RNA duplexes (siRNAs). The siRNAs are derived from the
processing of dsRNA by an RNase enzyme known as Dicer. siRNA duplex
products are recruited into a multi-protein siRNA complex termed
RISC (RNA Induced Silencing Complex). Without wishing to be bound
by any particular theory, a RISC is then believed to be guided to a
target nucleic acid (suitably mRNA), where the siRNA duplex
interacts in a sequence-specific way to mediate cleavage in a
catalytic fashion. Small interfering RNAs that can be used in
accordance with the present invention can be synthesized and used
according to procedures that are well known in the art and that
will be familiar to the ordinarily skilled artisan. Small
interfering RNAs for use in the methods of the present invention
suitably comprise between about 1 to about 50 nucleotides (nt). In
examples of non limiting embodiments, siRNAs can comprise about 5
to about 40 nt, about 5 to about 30 nt, about 10 to about 30 nt,
about 15 to about 25 nt, or about 20-25 nucleotides.
[0039] Selection of appropriate oligonucleotides is facilitated by
using computer programs that automatically align nucleic acid
sequences and indicate regions of identity or homology. Such
programs are used to compare nucleic acid sequences obtained, for
example, by searching databases such as GenBank or by sequencing
PCR products. Comparison of nucleic acid sequences from a range of
species allows the selection of nucleic acid sequences that display
an appropriate degree of identity between species. In the case of
genes that have not been sequenced, Southern blots are performed to
allow a determination of the degree of identity between genes in
target species and other species. By performing Southern blots at
varying degrees of stringency, as is well known in the art, it is
possible to obtain an approximate measure of identity. These
procedures allow the selection of oligonucleotides that exhibit a
high degree of complementarity to target nucleic acid sequences in
a subject to be controlled and a lower degree of complementarity to
corresponding nucleic acid sequences in other species. One skilled
in the art will realize that there is considerable latitude in
selecting appropriate regions of genes for use in the present
invention.
[0040] By "enzymatic RNA" is meant an RNA molecule with enzymatic
activity (Cech, (1988) J. American. Med. Assoc. 260, 3030-3035).
Enzymatic nucleic acids (ribozymes) act by first binding to a
target RNA. Such binding occurs through the target binding portion
of an enzymatic nucleic acid which is held in close proximity to an
enzymatic portion of the molecule that acts to cleave the target
RNA. Thus, the enzymatic nucleic acid first recognizes and then
binds a target RNA through base pairing, and once bound to the
correct site, acts enzymatically to cut the target RNA.
[0041] By "decoy RNA" is meant an RNA molecule that mimics the
natural binding domain for a ligand. The decoy RNA therefore
competes with natural binding target for the binding of a specific
ligand. For example, it has been shown that over-expression of HIV
trans-activation response (TAR) RNA can act as a "decoy" and
efficiently binds HIV tat protein, thereby preventing it from
binding to TAR sequences encoded in the HIV RNA. This is meant to
be a specific example. Those in the art will recognize that this is
but one example, and other embodiments can be readily generated
using techniques generally known in the art.
[0042] As used herein, the term "monomers" typically indicates
monomers linked by phosphodiester bonds or analogs thereof to form
oligonucleotides ranging in size from a few monomeric units, e.g.,
front about 3-4, to about several hundreds of monomeric units.
Analogs of phosphodiester linkages include: phosphorothioate,
phosphorodithioate, methylphosphomates, phosphoroselenoate,
phosphoramidate, and the like, as more fully described below.
[0043] The term "nucleotide" covers naturally occurring nucleotides
as well as nonnaturally occurring nucleotides. It should be clear
to the person skilled in the art that various nucleotides which
previously have been considered "non-naturally occurring" have
subsequently been found in nature. Thus, "nucleotides" includes not
only the known purine and pyrimidine heterocycles-containing
molecules, but also heterocyclic analogues and tautomers thereof.
Illustrative examples of other types of nucleotides are molecules
containing adenine, guanine, thymine, cytosine, uracil, purine,
xanthine, diaminopurine, 8-oxo-N6-methyladenine 7-deazaxanthine,
7-deazaguanine, N4,N4-ethanocytosin,
N6,N6-ethano-2,6-diaminopurine, 5-methylcytosine,
5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil,
pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin,
isocytosine, isoguanin, inosine and the "non-naturally occurring"
nucleotides described in Benner et al., U.S. Pat. No. 5,432,272.
The term "nucleotide" is intended to cover every and all of these
examples as well as analogues and tautomers thereof. Especially
interesting nucleotides are those containing adenine, guanine,
thymine, cytosine, and uracil, which are considered as the
naturally occurring nucleotides in relation to therapeutic and
diagnostic application in humans. Nucleotides include the natural
2'-deoxy and 2'-hydroxyl sugars, e.g., as described in Kornberg and
Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992) as
well as their analogs.
[0044] "Analogs" in reference to nucleotides includes synthetic
nucleotides having modified base moieties and/or modified sugar
moieties (see e.g., described generally by Scheit, Nucleotide
Analogs, John Wiley, New York, 1980; Freier & Altmann, (1997)
Nucl. Acid. Res., 25(22), 4429-4443, Toulme, J. J. (2001) Nature
Biotechnology 19:17-18; Manoharan M., (1999) Biochemica Biophysica
Acta 1489:117-139; Freier S. M., (1997) Nucleic Acid Research,
25:4429-4443, Uhlman, E., (2000) Drug Discovery & Development,
3: 203-213, Herdewin P., (2000) Antisense & Nucleic Acid Drug
Dev., 10:297-310); 2'-O, 3'-C-linked [3.2.0]
bicycloarabinonucleosides. Such analogs include synthetic
nucleotides designed to enhance binding properties, e.g., duplex or
triplex stability, specificity, or the like.
[0045] As used herein, "hybridization" means the pairing of
substantially complementary strands of oligomeric compounds. One
mechanism of pairing involves hydrogen bonding, which may be
Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding,
between complementary nucleoside or nucleotide bases (nucleotides)
of the strands of oligomeric compounds. For example, adenine and
thymine are complementary nucleotides which pair through the
formation of hydrogen bonds. Hybridization can occur under varying
circumstances.
[0046] An antisense compound is "specifically hybridizable" when
binding of the compound to the target nucleic acid interferes with
the normal function of the target nucleic acid to cause a
modulation of function and/or activity, and there is a sufficient
degree of complementarity to avoid non-specific binding of the
antisense compound to non-target nucleic acid sequences under
conditions in which specific binding is desired, i.e., under
physiological conditions in the case of in vivo assays or
therapeutic treatment, and under conditions in which assays are
performed in the case of in vitro assays.
[0047] As used herein, the phrase "stringent hybridization
conditions" or "stringent conditions" refers to conditions under
which a compound of the invention will hybridize to its target
sequence, but to a minimal number of other sequences. Stringent
conditions are sequence-dependent and will be different in
different circumstances and in the context of this invention,
"stringent conditions" under which oligomeric compounds hybridize
to a target sequence are determined by the nature and composition
of the oligomeric compounds and the assays in which they are being
investigated. In general, stringent hybridization conditions
comprise low concentrations (<0.15M) of salts with inorganic
cations such as Na++ or K++ (i.e., low ionic strength), temperature
higher than 20.degree. C.-25.degree. C. below the Tm of the
oligomeric compound:target sequence complex, and the presence of
denaturants such as formamide, dimethylformamide,
dimethylsulfoxide, or the detergent sodium dodecyl sulfate (SDS).
For example, the hybridization rate decreases 1.1% for each 1%
formamide. An example of a high stringency hybridization condition
is 0.1.times. sodium chloride-sodium citrate buffer (SSC)/0.1%
(w/v) SDS at 60' C. for 30 minutes.
[0048] "Complementary," as used herein, refers to the capacity for
precise pairing between two nucleotides on one or two oligomeric
strands. For example, if a nucleobase at a certain position of an
antisense compound is capable of hydrogen bonding with a nucleobase
at a certain position of a target nucleic acid, said target nucleic
acid being a DNA, RNA, or oligonucleotide molecule, then the
position of hydrogen bonding between the oligonucleotide and the
target nucleic acid is considered to be a complementary position.
The oligomeric compound and the further DNA, RNA, or
oligonucleotide molecule are complementary to each other when a
sufficient number of complementary positions in each molecule are
occupied by nucleotides which can hydrogen bond with each other.
Thus, "specifically hybridizable" and "complementary" are terms
which are used to indicate a sufficient degree of precise pairing
or complementarity over a sufficient number of nucleotides such
that stable and specific binding occurs between the oligomeric
compound and a target nucleic acid.
[0049] It is understood in the art that the sequence of an
oligomeric compound need not be 100% complementary to that of its
target nucleic acid to be specifically hybridizable. Moreover, an
oligonucleotide may hybridize over one or more segments such that
intervening or adjacent segments are not involved in the
hybridization event (e.g., a loop structure, mismatch or hairpin
structure). The oligomeric compounds of the present invention
comprise at least about 70%, or at least about 75%, or at least
about 80%, or at least about 85%, or at least about 90%, or at
least about 95%, or at least about 99% sequence complementarity to
a target region within the target nucleic acid sequence to which
they are targeted. For example, an antisense compound in which 18
of 20 nucleotides of the antisense compound are complementary to a
target region, and would therefore specifically hybridize, would
represent 90 percent complementarity. In this example, the
remaining noncomplementary nucleotides may be clustered or
interspersed with complementary nucleotides and need not be
contiguous to each other or to complementary nucleotides. As such,
an antisense compound which is 18 nucleotides in length having 4
(four) noncomplementary nucleotides which are flanked by two
regions of complete complementarity with the target nucleic acid
would have 77.8% overall complementarity with the target nucleic
acid and would thus fill within the scope of the present invention.
Percent complementarity of an antisense compound with a region of a
target nucleic acid can be determined routinely using BLAST
programs (basic local alignment search tools) and PowerBLAST
programs known in the art. Percent homology, sequence identity or
complementarity, can be determined by, for example, the Gap program
(Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics
Computer Group, University Research Park, Madison Wis.), using
default settings, which uses the algorithm of Smith and Waterman
(Adv. Appl. Math., (1981) 2, 482-489).
[0050] As used herein, the term "Thermal Melting Point (Tm)" refers
to the temperature, under defined ionic strength, pH, and nucleic
acid concentration, at which 50% of the oligonucleotides
complementary to the target sequence hybridize to the target
sequence at equilibrium. Typically, stringent conditions will be
those in which the salt concentration is at least about 0.01 to 1.0
M Na ion concentration (or other salts) at pH 7.0 to 8.3 and the
temperature is at least about 30.degree. C. for short
oligonucleotides (e.g., 10 to 50 nucleotide). Stringent conditions
may also be achieved with the addition of destabilizing agents such
as formamide.
[0051] As used herein, "modulation" means either an increase
(stimulation) or a decrease (inhibition) in the expression of a
gene.
[0052] The term "variant", when used in the context of a
polynucleotide sequence, may encompass a polynucleotide sequence
related to a wild type gene. This definition may also include, for
example, "allelic," "splice," "species," or "polymorphic" variants.
A splice variant may have significant identity to a reference
molecule, but will generally have a greater or lesser number of
polynucleotides due to alternate splicing of exons during mRNA
processing. The corresponding polypeptide may possess additional
functional domains or an absence of domains. Species variants are
polynucleotide sequences that vary from one species to another. Of
particular utility in the invention are variants of wild type gene
products. Variants may result from at least one mutation in the
nucleic acid sequence and may result in altered mRNAs or in
polypeptides whose structure or function may or may not be altered.
Any given natural or recombinant gene may have none, one, or many
allelic forms. Common mutational changes that give rise to variants
are generally ascribed to natural deletions, additions, or
substitutions of nucleotides. Each of these types of changes may
occur alone, or in combination with the others, one or more times
in a given sequence.
[0053] The resulting polypeptides generally will have significant
amino acid identity relative to each other. A polymorphic variant
is a variation in the polynucleotide sequence of a particular gene
between individuals of a given species. Polymorphic variants also
may encompass "single nucleotide polymorphisms" (SNPs,) or single
base mutations in which the polynucleotide sequence varies by one
base. The presence of SNPs may be indicative of, for example, a
certain population with a propensity for a disease state, that is
susceptibility versus resistance.
[0054] Derivative poly-nucleotides include nucleic acids subjected
to chemical modification, for example, replacement of hydrogen by
an alkyl, acyl, or amino group. Derivatives, e.g., derivative
oligonucleotides, may comprise non-naturally-occurring portions,
such as altered sugar moieties or inter-sugar linkages. Exemplary
among these are phosphorothioate and other sulfur containing
species which are known in the art. Derivative nucleic acids may
also contain labels, including radionucleotides, enzymes,
fluorescent agents, chemiluminescent agents, chromogenic agents,
substrates, cofactors, inhibitors, magnetic particles, and the
like.
[0055] A "derivative" polypeptide or peptide is one that is
modified, for example, by glycosylation, pegylation,
phosphorylation, sulfation, reduction/alkylation, acylation,
chemical coupling, or mild formalin treatment. A derivative may
also be modified to contain a detectable label, either directly or
indirectly, including, but not limited to, a radioisotope,
fluorescent, and enzyme label.
[0056] As used herein, the term "animal" or "patient" is meant to
include, for example, humans, sheep, elks, deer, mule deer, minks,
mammals, monkeys, horses, cattle, pigs, goats, dogs, cats, rats,
mice, birds, chicken, reptiles, fish, insects and arachnids.
[0057] "Mammal" covers warm blooded mammals that are typically
under medical care (e.g., humans and domesticated animals).
Examples include feline, canine, equine, bovine, and human, as well
as just human.
[0058] "Treating" or "treatment" covers the treatment of a
disease-state in a mammal, and includes: (a) preventing the
disease-state from occurring in a mammal, in particular, when such
mammal is predisposed to the disease-state but has not yet been
diagnosed as having it; (b) inhibiting the disease-state, e.g.,
arresting it development; and/or (c) relieving the disease-state,
e.g., causing regression of the disease state until a desired
endpoint is reached. Treating also includes the amelioration of a
symptom of a disease (e.g., lessen the pain or discomfort), wherein
such amelioration may or may not be directly affecting the disease
(e.g., cause, transmission, expression, etc.).
[0059] As used herein, "cancer" refers to all types of cancer or
neoplasm or malignant tumors found in mammals, including, but not
limited to: leukemias, lymphomas, melanomas, carcinomas and
sarcomas. The cancer manifests itself as a "tumor" or tissue
comprising malignant cells of the cancer. Examples of tumors
include sarcomas and carcinomas such as, but not limited to:
fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic
sarcoma, chordoma, angiosarcoma, endotheliosarcoma,
lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma,
mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma,
colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer,
prostate cancer, squamous cell carcinoma, basal cell carcinoma,
adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma,
papillary carcinoma, papillary adenocarcinomas, cystadonocarcinoma,
medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma,
hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal
carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung
carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial
carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma,
ependymoma, pinealoma, hemangioblastoma, acoustic neuroma,
oligodendroglioma, meningioma, melanoma, neuroblastoma, and
retinoblastoma. Additional cancers which can be treated by the
disclosed composition according to the invention include but not
limited to, for example, Hodgkin's Disease, Non-Hodgkin's Lymphoma,
multiple myeloma, neuroblastoma, breast cancer, ovarian cancer,
lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary
macroglobulinemia, small-cell lung tumors, primary brain tumors,
stomach cancer, colon cancer, malignant pancreatic insulanoma,
malignant carcinoid, urinary bladder cancer, gastric cancer,
premalignant skin lesions, testicular cancer, lymphomas, thyroid
cancer, neuroblastoma, esophageal cancer, genitourinary tract
cancer, malignant hypercalcemia, cervical cancer, endometrial
cancer, adrenal cortical cancer, and prostate cancer.
[0060] "Neurological disease or disorder" refers to any disease or
disorder of the nervous system and/or visual system, "Neurological
disease or disorder" include disease or disorders that involve the
central nervous system (brain, brainstem and cerebellum), the
peripheral nervous system (including cranial nerves), and the
autonomic nervous system (parts of which arc located in both
central and peripheral nervous system). Examples of neurological
disorders include but are not limited to, headache, stupor and
coma, dementia, seizure, sleep disorders, trauma, infections,
neoplasms, neuroopthalmology, movement disorders, demyelinating
diseases, spinal cord disorders, and disorders of peripheral
nerves, muscle and neuromuscular junctions. Addiction and mental
illness, include, but are not limited to, bipolar disorder and
schizophrenia, are also included in the definition of neurological
disorder. The following is a list of several neurological
disorders, symptoms, signs and syndromes that can be treated using
compositions and methods according to the present invention:
acquired epileptiform aphasia; acute disseminated
encephalomyelitis; adrenoleukodystrophy; age-related macular
degeneration; agenesis of the corpus callosum; agnosia; Aicardi
syndrome; Alexander disease; Alpers' disease; alternating
hemiplegia; Vascular dementia; amyotrophic lateral sclerosis;
anencephaly; Angelman syndrome; angiomatosis; anoxia; aphasia;
apraxia; arachnoid cysts; arachnoiditis; Anronl-Chiari
malformation; arteriovenous malformation; Asperger syndrome; ataxia
telegiectasia; attention deficit hyperactivity disorder; autism;
autonomic dysfunction; back pain; Batten disease; Behcet's disease;
Bell's palsy; benign essential blepharospasm; benign focal;
amyotrophy: benign intracranial hypertension; Binswanger's disease;
blepharospasm; Bloch Sulzberger syndrome; brachial plexus injury;
brain abscess; brain injury; brain tumors (including glioblastoma
multiforme); spinal tumor; Brown-Sequard syndrome; Canavan disease;
carpal tunnel syndrome; causalgia; central pain syndrome; central
pontine myelinolysis; cephalic disorder; cerebral aneurysm;
cerebral arteriosclerosis; cerebral atrophy; cerebral gigantism;
cerebral palsy; Charcot-Marie-Tooth disease; chemotherapy-induced
neuropathy and neuropathic pain; Chiari malformation; chorea;
chronic inflammatory demyelinating polyneuropathy; chronic pain;
chronic regional pain syndrome; Coffin Lowry syndrome; coma,
including persistent vegetative state; congenital facial diplegia;
corticobasal degeneration; cranial arteritis; craniosynostosis;
Creutzfeldt-Jakob disease; cumulative trauma disorders: Cushing's
syndrome; cytomegalic inclusion body disease; cytomegalovirus
infection; dancing eyes-dancing feet syndrome; DandyWalker
syndrome; Dawson disease; De Morsier's syndrome; Dejerine-Klumke
palsy; dementia; dermatomyositis; diabetic neuropathy; diffuse
sclerosis; dysautonomia; dysgraphia; dyslexia: dystonias; early
infantile epileptic encephalopathy; empty sella syndrome;
encephalitis; encephaloceles; encephalotrigeminal angiomatosis;
epilepsy; Erb's palsy; essential tremor; Fabry's disease; Fahr's
syndrome; fainting; familial spastic paralysis; febrile seizures;
Fisher syndrome; Friedreich's ataxia; fronto-temporal dementia and
other "tauopathies"; Gaucher's disease; Gerstmann's syndrome; giant
cell arteritis; giant cell inclusion disease; globoid cell
leukodystrophy; Guillain-Barre syndrome; HTLV-1-associated
myelopathy; Hallervorden-Spatz disease; head injury; headache;
hemifacial spasm; hereditary spastic paraplegia; heredopathia
atactic a polyneuritiformis; herpes zoster oticus; herpes zoster;
Hirayama syndrome; HIVassociated dementia and neuropathy (also
neurological manifestations of AIDS); holoprosencephaly;
Huntington's disease and other polyglutamine repeat diseases;
hydrimencephaly; hydrocephalus; hypercortisolism; hypoxia;
immune-mediated encephalomyelitis; inclusion body myositis;
incontinentia pigmenti; infantile phytanic acid storage disease;
infantile refsum disease; infantile spasms; inflammatory myopathy;
intracranial cyst; intracranial hypertension; Joubert syndrome;
Keams-Sayre syndrome; Kennedy disease Kinsboume syndrome; Klippel
Feil syndrome; Krabbe disease; Kugelberg-Welander disease; kuru;
Lafora disease; Lambert-Eaton myasthenic syndrome; Landau-Kleffner
syndrome; lateral medullary (Wallenberg) syndrome; learning
disabilities; Leigh's disease; Lennox-Gustaut syndrome; Lesch-Nyhan
syndrome; leukodystrophy; Lewy body dementia; Lissencephaly;
locked-in syndrome; Lou Gehrig's disease (i.e., motor neuron
disease or amyotrophic lateral sclerosis); lumbar disc disease;
Lyme disease--neurological sequelae; Machado-Joseph disease;
macrencephaly; megalencephaly; Melkersson-Rosenthal syndrome;
Menieres disease; meningitis; Menkes disease; metachromatic
leukodystrophy; microcephaly; migraine; Miller Fisher syndrome;
mini-strokes; mitochondrial myopathies; Mobius syndrome; monomelic
amyotrophy; motor neuron disease; Moyamoya disease;
mucopolysaccharidoses; multi-infarct dementia: multifocal motor
neuropathy; multiple sclerosis and other demyelinating disorders;
multiple system atrophy with postural hypotension; p muscular
dystrophy, myasthenia gravis; myelinoelastic diffuse sclerosis;
myoclonic encephalopathy of infants; myoclonus; myopathy; myotonia
congenital: narcolepsy; neurofibromatosis; neuroleptic malignant
syndrome; neurological manifestations of AIDS; neurological
sequelae oflupus: neuramyotonia; neuronal ceroid lipofuseinosis;
neuronal migration disorders; Niemann-Pick disease;
O'Sullivan-McLeod syndrome; occipital neuralgia; occult spinal
dysraphism sequence; Ohtahara syndrome; olivopontocerebellar
atrophy; opsoclonus myoclonus; optic neuritis; orthostatic
hypotension; overuse syndrome; paresthesia; Neurodegenerative
disease or disorder (Parkinson's disease, Huntington's disease,
Alzheimer's disease, amyotrophic lateral sclerosis (ALS), dementia,
multiple sclerosis and other diseases and disorders associated with
neuronal cell death); paramyotonia congenital; paraneoplastic
diseases; paroxysmal attacks; Parry Romberg syndrome;
Pelizaeus-Merzbacher disease; periodic paralyses; peripheral
muropathy; painful neuropathy and neuropathic pain; persistent
vegetative state; pervasive developmental disorders; photic sneeze
reflex; phytanic acid storage disease; Pick's disease; pinched
nerve; pituitary tumors; polymyositis; porencephaly; post-polio
syndrome; postherpetic neuralgia; postinfections encephalomyelitis;
postural hypotension; Prader-Willi syndrome; primary lateral
sclerosis; prion diseases: progressive hemifacial atrophy;
progressive multifocalleukoencephalopathy; progressive sclerosing
poliodystrophy; progressive supranuclear palsy; pseudotumor
cerebri; Ramsay-Hunt syndrome (types I and II); Rasmussen's
encephalitis; reflex sympathetic dystrophy syndrome; Refsum
disease; repetitive motion disorders; repetitive stress injuries;
restless legs syndrome; retrovirus-associated myelopathy; Refsum
syndrome; Reye's syndrome; Saint Vitus dance; Sandhoff disease;
Schilder's disease; schizencephaly: septo-optic dysplasia; shaken
baby syndrome; shingles; Shy-Drager syndrome; Sjogren's syndrome;
sleep apnea; Soto's syndrome; spasticity; spina bifida; spinal cord
injury; spinal cord tumors; spinal muscular atrophy; Stiff-Person
syndrome; stroke; Sturge-Weber syndrome; subacute sclerosing
panencephalitis; subcortical arteriosclerotic encephalopathy;
Sydenham chorea; syncope; syringomyelia; tardive dyskinesia;
Tay-Sachs disease; temporal arteritis; tethered spinal cord
syndrome; Thomsen disease; thoracic outlet syndrome; Tic
Douloureux; Todd's paralysis; Tourette syndrome; transient ischemic
attack; transmissible spongiform encephalopathies; transverse
myelitis: traumatic brain injury; tremor; trigeminal neuralgia;
tropical spastic paraparesis; tuberous sclerosis; vascular dementia
(multi-infarct dementia); vasculitis including temporal arteritis;
Von Hippel-Lindau disease; Wallenberg's syndrome; Werdnig-Hoffman
disease; West syndrome; whiplash; Williams syndrome; Wildon's
disease; and Zellweger syndrome.
Polynucleotides and Oligonucleotide Compositions and Molecules
[0061] Targets: In one embodiment, the targets comprise nucleic
acid sequences of Insulin Receptor Substrate 2 (IRS2) and
Transcription factor E3 (TFE3), including without limitation sense
and/or antisense noncoding and/or coding sequences associated with
TFE3.
[0062] TFE3, a basic helix-loop-helix (bHLH) protein, as a
transactivator of metabolic genes that are regulated through an
E-box in their promoters. Adenovirus-mediated expression of TFE3 in
hepatocytes in culture and in vivo strongly activated expression of
IRS-2 and Akt and enhanced phosphorylation of insulin-signaling
kinases such as Akt, glycogen synthase kinase 3.beta. and p70S6
kinase, TFE3 is a bHLH transcription factor that strongly activates
various insulin signaling molecules, protecting against the
development of insulin resistance and the metabolic syndrome.
[0063] Regulation of IRS-2 is the primary site where TFE3 in
synergy with Foxo1, and SREBP-1c converge. Taken together,
TFE3/Foxo1 andSREBP-1c reciprocally regulate IRS-2 expression and
insulin sensitivity in the liver.
[0064] Members of the IRS-protein family are tyrosine
phosphorylated by the receptors for insulin and IGF-1, as well as
certain cytokines receptors coupled to Janus kinases. At least four
IRS-proteins occur in mammals. IRS-1 and IRS-2 are widely
expressed; IRS-3 is restricted to adipose tissue, .beta.-cells, and
possibly liver; and IRS-4 is expressed in the thymus, brain, and
kidney. IRS-proteins have a conserved amino terminus composed of
adjacent pleckstrin homology and phosphotyrosine-binding domains
that mediate coupling to activated receptor tyrosine kinases.
[0065] In an embodiment, antisense oligonucleotides are used to
prevent or treat diseases or disorders associated with IRS2 family
members. Exemplary Insulin Receptor Substrate 2 (IRS2) mediated
diseases and disorders which can be treated with cell/tissues
regenerated from stem cells obtained using the antisense compounds
comprise: a disease or disorder associated with abnormal function
and/or expression of IRS2 and/or TFE3, a neurological disease or
disorder (e.g. Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis etc.), a disease or disorder
associated with insulin resistance, diabetes, an insulin resistant
non diabetic state (e.g., obesity, impaired glucose tolerance
(IGT), Metabolic Syndrome etc.), a hepatic disease or disorder, a
disease or disorder associated with kidney growth and development,
a disease or disorder associated with skeletal muscle growth and/or
metabolism, a disease or disorder associated with carbohydrate
metabolism, a weight disorder, Polycystic Ovary Syndrome,
atherosclerosis, cancer, a disease or disorder associated with
apoptosis, a disease or disorder associated with aging and
senescence.
[0066] In an embodiment, modulation IRS2 by one or more antisense
oligonucleotides is administered to a patient in need thereof, for
athletic enhancement and body building.
[0067] In an embodiment, modulation of IRS2 by one or more
antisense oligonucleotides is administered to a patient in need
thereof, to prevent or treat any disease or disorder related to
IRS2 or TFE3 abnormal expression, function, activity as compared to
a normal control.
[0068] In an embodiment, the oligonucleotides are specific for
polynucleotides of IRS2, which includes, without limitation
noncoding regions. The IRS2 targets comprise variants of IRS2 and
TFE3; mutants of IRS2 and TFE3, including SNPs; noncoding sequences
of IRS2 and TFE3; alleles, fragments and the like. Preferably the
oligonucleotide is an antisense RNA molecule.
[0069] In accordance with embodiments of the invention, the target
nucleic acid molecule is not limited to IRS2 or TFE3
polynucleotides alone but extends to any of the isoforms,
receptors, homologs, non-coding regions and the like of IRS2 and
TFE3.
[0070] In an embodiment, an oligonucleotide targets a natural
antisense sequence (natural antisense to the coding and non-coding
regions) of IRS2 and TFE3 targets, including, without limitation,
variants, alleles, homologs, mutants, derivatives, fragments and
complementary sequences thereto. Preferably the oligonucleotide is
an antisense RNA or DNA molecule.
[0071] In an embodiment, the oligomeric compounds of the present
invention also include variants in which a different base is
present at one or more of the nucleotide positions in the compound.
For example, if the first nucleotide is an adenine, variants may be
produced which contain thymidine, guanosine, cytidine or other
natural or unnatural nucleotides at this position. This may be done
at any of the positions of the antisense compound. These compounds
are then tested using the methods described herein to determine
their ability to inhibit expression of a target nucleic acid.
[0072] In some embodiments, homology, sequence identity or
complementarity, between the antisense compound and target is from
about 50%, to about 60%. In some embodiments, homology, sequence
identity or complementarity, is from about 60%, to about 70%. In
some embodiments, homology, sequence identity or complementarity,
is from about 70% to about 80%. In some embodiments, homology,
sequence identity or complementarity, is from about 80% to about
90%. In some embodiments, homology, sequence identity or
complementarity, is about 90%, about 92%, about 94%, about 95%,
about 96%, about 97%, about 98%, about 99% or about 100%.
[0073] An antisense compound is specifically hybridizable when
binding of the compound to the target nucleic acid interferes with
the normal function of the target nucleic acid to cause a loss of
activity, and there is a sufficient degree of complementarity to
avoid non-specific binding of the antisense compound to non-target
nucleic acid sequences under conditions in which specific binding
is desired. Such conditions include, i.e., physiological conditions
in the case of in vivo assays or therapeutic treatment, and
conditions in which assays are performed in the case of in vitro
assays.
[0074] An antisense compound, whether DNA, RNA, chimeric,
substituted etc, is specifically hybridizable when binding of the
compound to the target DNA or RNA molecule interferes with the
normal function of the target DNA or RNA to cause a loss of
utility, and there is a sufficient degree of complementarily to
avoid non-specific binding of the antisense compound to non-target
sequences under conditions in which specific binding is desired,
i.e., under physiological conditions in the case of in vivo assays
or therapeutic treatment, and in the case of in vitro assays, under
conditions in which the assays are performed.
[0075] In an embodiment, targeting of IRS2 or TFE3 including
without limitation, antisense sequences which are identified and
expanded, using for example, PCR, hybridization etc., one or more
of the sequences set forth as SEQ ID NOS: 2 and 3, and the like,
modulate the expression or function of IRS2. In one embodiment,
expression or function is up-regulated as compared to a control. In
an embodiment, expression or function is down-regulated as compared
to a control.
[0076] In an embodiment, oligonucleotides comprise nucleic acid
sequences set forth as SEQ ID NOS: 4 to 9 including antisense
sequences which are identified and expanded, using for example,
PCR, hybridization etc. These oligonucleotides can comprise one or
more modified nucleotides, shorter or longer fragments, modified
bonds and the like. Examples of modified bonds or internucleotide
linkages comprise phosphorothioate, phosphorodithioate or the like.
In an embodiment, the nucleotides comprise a phosphorus derivative.
The phosphorus derivative (or modified phosphate group) which may
be attached to the sugar or sugar analog moiety in the modified
oligonucleotides of the present invention may be a monophosphate,
diphosphate, triphosphate, alkylphosphate, alkanephosphate,
phosphorothioate and the like. The preparation of the above-noted
phosphate analogs, and their incorporation into nucleotides,
modified nucleotides and oligonucleotides, per se, is also known
and need not be described here.
[0077] The specificity and sensitivity of antisense is also
harnessed by those of skill in the art for therapeutic uses.
Antisense oligonucleotides have been employed as therapeutic
moieties in the treatment of disease states in animals and man.
Antisense oligonucleotides have been safely and effectively
administered to humans and numerous clinical trials are presently
underway. It is thus established that oligonucleotides can be
useful therapeutic modalities that can be configured to be useful
in treatment regimes for treatment of cells, tissues and animals,
especially humans.
[0078] In embodiments of the present invention oligomeric antisense
compounds, particularly oligonucleotides, bind to target nucleic
acid molecules and modulate the expression and/or function of
molecules encoded by a target gene. The functions of DNA to be
interfered comprise, for example, replication and transcription.
The functions of RNA to be interfered comprise all vital functions
such as, for example, translocation of the RNA to the site of
protein translation, translation of protein from the RNA, splicing
of the RNA to yield one or more mRNA species, and catalytic
activity which may be engaged in or facilitated by the RNA. The
functions may be up-regulated or depending on the functions
desired.
[0079] The antisense compounds, include, antisense oligomeric
compounds, antisense oligonucleotides, external guide sequence
(EGS) oligonucleotides, alternate splicers, primers, probes, and
other oligomeric compounds that hybridize to at least a portion of
the target nucleic acid. As such, these compounds may be introduced
in the form of single-stranded, double-stranded, partially
single-stranded, or circular oligomeric compounds.
[0080] Targeting an antisense compound to a particular nucleic acid
molecule, in the context of this invention, can be a multistep
process. The process usually begins with the identification of a
target nucleic acid whose function is to be modulated. This target
nucleic acid may be, for example, a cellular gene (or mRNA
transcribed from the gene) whose expression is associated with a
particular disorder or disease state, or a nucleic acid molecule
from an infectious agent. In the present invention, the target
nucleic acid encodes IRS2 or TFE3.
[0081] The targeting process usually also includes determination of
at least one target region, segment, or site within the target
nucleic acid for the antisense interaction to occur such that the
desired effect, e.g., modulation of expression, will result. Within
the context of the present invention, the term "region" is defined
as a portion of the target nucleic acid having at least one
identifiable structure, function, or characteristic. Within regions
of target nucleic acids are segments. "Segments" are defined as
smaller or sub-portions of regions within a target nucleic acid.
"Sites," as used in the present invention, are defined as positions
within a target nucleic acid.
[0082] In an embodiment, the antisense oligonucleotides bind to the
natural antisense sequences of Insulin Receptor Substrate 2 (IRS2)
or Transcription factor E3 (TFE3) and modulate the expression
and/or function of IRS2 (SEQ ID NO: 1). Examples of antisense
sequences include SEQ ID NOS: 2 to 9.
[0083] In an embodiment, the antisense oligonucleotides bind to one
or more segments of Insulin Receptor Substrate 2 (IRS2) or
Transcription factor E3 (TFE3) polynucleotides and modulate the
expression and/or function of IRS2. The segments comprise at least
five consecutive nucleotides of the IRS2 or TFE3 sense or antisense
polynucleotides.
[0084] In an embodiment, the antisense oligonucleotides are
specific for natural antisense sequences of IRS2 or TFE3 wherein
binding of the oligonucleotides to the natural antisense sequences
of IRS2 or TFE3 modulate expression and/or function of IRS2.
[0085] In an embodiment, oligonucleotide compounds comprise
sequences set forth as SEQ ID NOS: 4 to 9, antisense sequences
which are identified and expanded, using for example, PCR,
hybridization etc These oligonucleotides can comprise one or more
modified nucleotides, shorter or longer fragments, modified bonds
and the like. Examples of modified bonds or internucleotide
linkages comprise phosphorothioate, phosphorodithioate or the like.
In an embodiment, the nucleotides comprise a phosphorus derivative.
The phosphorus derivative (or modified phosphate group) which may
be attached to the sugar or sugar analog moiety in the modified
oligonucleotides of the present invention may be a monophosphate,
diphosphate, triphosphate, alkylphosphate, alkanephosphate,
phosphorothioate and the like. The preparation of the above-noted
phosphate analogs, and their incorporation into nucleotides,
modified nucleotides and oligonucleotides, per se, is also known
and need not be described here.
[0086] Since, as is known in the art, the translation initiation
codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in
the corresponding DNA molecule), the translation initiation codon
is also referred to as the "AUG codon," the "start codon" or the
"AUG start codon". A minority of genes has a translation initiation
codon having the RNA sequence 5'-GUG, 5'-UUG or or 5'-CUG; and
5'-AUA, 5'-ACG and 5-CUG have been shown to function in vivo. Thus,
the terms "translation initiation codon" and "start codon" can
encompass many codon sequences, even though the initiator amino
acid in each instance is typically methionine (in eukaryotes) or
formylmethionine (in prokaryotes). Eukaryotic and prokaryotic genes
may have two or more alternative start codons, any one of which may
be preferentially utilized for translation initiation in a
particular cell type or tissue, or under a particular set of
conditions. In the context of the invention, "start codon" and
"translation initiation codon" refer to the codon or codons that
are used in vivo to initiate translation of an mRNA transcribed
from a gene encoding Insulin Insulin Receptor Substrate 2 (IRS2) or
Transcription factor E3 (TFE3), regardless of the sequence(s) of
such codons. A translation termination codon (or "stop codon") of a
gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and
5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and
5'-TGA, respectively).
[0087] The terms "start codon region" and "translation initiation
codon region" refer to a portion of such an mRNA or gene that
encompasses from about 25 to about 50 contiguous nucleotides in
either direction (i.e., 5' or 3') from a translation initiation
codon. Similarly, the terms "stop codon region" and "translation
termination codon region" refer to a portion of such an mRNA or
gene that encompasses from about 25 to about 50 contiguous
nucleotides in either direction (i.e., 5' or 3') from a translation
termination codon. Consequently, the "start codon region" (or
"translation initiation codon region") and the "stop codon region"
(or "translation termination codon region") are all regions that
may be targeted effectively with the antisense compounds or the
present invention.
[0088] The open reading frame (ORF) or "coding region," which is
known in the art to refer to the region between the translation
initiation codon and the translation termination codon, is also a
region which may be targeted effectively. Within the context of the
present invention, a targeted region is the intragenic region
encompassing the translation initiation or termination codon of the
open reading frame (ORF) of a gene.
[0089] Another target region includes the 5' untranslated region
(5'UTR), known in the art to refer to the portion of an mRNA in the
5' direction from the translation initiation codon, and thus
including nucleotides between the 5' cap site and the translation
initiation codon of an mRNA (or corresponding nucleotides on the
gene). Still another target region includes the 3' untranslated
region (3'UTR), known in the art to refer to the portion of an mRNA
in the 3' direction from the translation termination codon, and
thus including nucleotides between the translation termination
codon and 3' end of an mRNA (or corresponding nucleotides on the
gene). The 5' cap site of an mRNA comprises an N7-methylated
guanosine residue joined to the 5'-most residue of the mRNA via a
5'-5' triphosphate linkage. The 5' cap region of an mRNA is
considered to include the 5' cap structure itself as well as the
first 50 nucleotides adjacent to the cap site. Another target
region for this invention is the 5' cap region.
[0090] Although some eukaryotic mRNA transcripts are directly
translated, many contain one or more regions, known as "introns."
which are excised from a transcript before it is translated. The
remaining (and therefore translated) regions are known as "exons"
and are spliced together to form a continuous mRNA sequence. In one
embodiment, targeting splice sites, i.e., intron-exon junctions or
exon-intron junctions, is particularly useful in situations where
aberrant splicing is implicated in disease, or where an
overproduction of a particular splice product is implicated in
disease. An aberrant fusion junction due to rearrangement or
deletion is another embodiment of a target site. mRNA transcripts
produced via the process of splicing of two (or more) mRNAs from
different gene sources are known as "fusion transcripts", introns
can be effectively targeted using antisense compounds targeted to,
for example, DNA or pre-mRNA.
[0091] In an embodiment, the antisense oligonucleotides bind to
coding and/or non-coding regions of a target polynucleotide and
modulate the expression and/or function of the target molecule.
[0092] In an embodiment, the antisense oligonucleotides bind to
natural antisense polynucleotides and modulate the expression
and/or function of the target molecule.
[0093] In an embodiment, the antisense oligonucleotides bind to
sense polynucleotides and modulate the expression and/or function
of the target molecule.
[0094] Alternative RNA transcripts can be produced from the same
genomic region of DNA. These alternative transcripts are generally
known as "variants". More specifically, "pre-mRNA varians" are
transcripts produced from the same genomic DNA that differ from
other transcripts produced from the same genomic DNA in either
their start or stop position and contain both intronic and exonic
sequence.
[0095] Upon excision of one or more exon or intron regions, or
portions thereof during splicing, pre-mRNA variants produce smaller
"mRNA variants". Consequently, mRNA variants are processed pre-mRNA
variants and each unique pre-mRNA variant must always produce a
unique mRNA variant as a result of splicing. These mRNA variants
are also known as "alternative splice variants". If no splicing of
the pre-mRNA variant occurs then the pre-mRNA variant is identical
to the mRNA variant.
[0096] Variants can be produced through the use of alternative
signals to start or stop transcription. Pre-mRNAs and mRNAs can
possess more than one start codon or stop codon. Variants that
originate from a pre-mRNA or mRNA that use alternative start codons
are known as "alternative start variants" of that pre-mRNA or mRNA.
Those transcripts that use an alternative stop codon are known as
"alternative stop variants" of that pre-mRNA or mRNA. One specific
type of alternative stop variant is the "polyA variant" in which
the multiple transcripts produced result from the alternative
selection of one of the "polyA stop signals" by the transcription
machinery, thereby producing transcripts that terminate at unique
polyA sites. Within the context of the invention, the types of
variants described herein are also embodiments of target nucleic
acids.
[0097] The locations on the target nucleic acid to which the
antisense compounds hybridize are defined as at least a
5-nucleotide long portion of a target region to which an active
antisense compound is targeted.
[0098] While the specific sequences of certain exemplary target
segments are set forth herein, one of skill in the art will
recognize that these serve to illustrate and describe particular
embodiments within the scope of the present invention. Additional
target segments are readily identifiable by one having ordinary
skill in the art in view of this disclosure.
[0099] Target segments 5-100 nucleotides in length comprising a
stretch of at least five (5) consecutive nucleotides selected from
within the illustrative preferred target segments are considered to
be suitable for targeting as well.
[0100] Target segments can include DNA or RNA sequences that
comprise at least the 5 consecutive nucleotides from the
5'-terminus of one of the illustrative preferred target segments
(the remaining nucleotides being a consecutive stretch of the same
DNA or RNA beginning immediately upstream of the 5'-terminus of the
target segment and continuing until the DNA or RNA contains about 5
to about 100 nucleotides). Similarly preferred target segments are
represented by DNA or RNA sequences that compose at least the 5
consecutive nucleotides from the 3'-terminus of one of the
illustrative preferred target segments (the remaining nucleotides
being a consecutive stretch of the same DNA or RNA beginning
immediately downstream of the 3'-terminus of the target segment and
continuing until the DNA or RNA contains about 5 to about 100
nucleotides). One having skill in the art armed with the target
segments illustrated herein will be able, without undue
experimentation, to identify further preferred target segments.
[0101] Once one or more target regions, segments or sites have been
identified, antisense compounds are chosen which are sufficiently
complementary to the target, i.e., hybridize sufficiently well and
with sufficient specificity, to give the desired effect.
[0102] In embodiments of the invention the oligonucleotides bind to
an antisense strand of a particular target. The oligonucleotides
are at least 5 nucleotides in length and can be synthesized so each
oligonucleotide targets overlapping sequences such that
oligonucleotides are synthesized to cover the entire length of the
target polynucleotide. The targets also include coding as well as
non coding regions.
[0103] In one embodiment, it is preferred to target specific
nucleic acids by antisense oligonucleotides. Targeting an antisense
compound to a particular nucleic acid, is a multistep process. The
process usually begins with the identification of a nucleic acid
sequence whose function is to be modulated. This may be, for
example, a cellular gene (or mRNA transcribed from the gene) whose
expression is associated with a particular disorder or disease
state, or a non coding polynucleotide such as for example, non
coding RNA (ncRNA).
[0104] RNAs can be classified into (1) messenger RNAs (mRNAs),
which are translated into proteins, and (2) non-protein-coding RNAs
(ncRNAs), ncRNAs comprise microRNAs, antisense transcripts and
other Transcriptional Units (TU) containing a high density of stop
codons and lacking any extensive "Open Reading Frame", Many ncRNAs
appear to start from initiation sites in 3' untranslated regions
(3'UTRs) of protein-coding loci. ncRNAs are often rare and at least
half of the ncRNAs that have been sequenced by the FANTOM
consortium seem not to be polyadenylated. Most researchers have for
obvious reasons focused on polyadenylated mRNAs that are processed
and exported to the cytoplasm. Recently, it was shown that the set
of non-polyadenylated nuclear RNAs may be very large, and that many
such transcripts arise from so-called intergenic regions. The
mechanism by which ncRNAs may regulate gene expression is by base
pairings with target transcripts. The RNAs that function by base
pairing can be grouped into (1) cis encoded RNAs that are encoded
at the same genetic location, but on the opposite strand to the
RNAs they act upon and therefore display perfect complementarity to
their target, and (2) trans-encoded RNAs that are encoded at a
chromosomal location distinct from the RNAs they act upon and
generally do not exhibit perfect base-pairing potential with their
targets.
[0105] Without wishing to be bound by theory, perturbation of an
antisense polynucleotide by the antisense oligonucleotides
described herein can alter the expression of the corresponding
sense messenger RNAs. However, this regulation can either be
discordant (antisense knockdown results in messenger RNA elevation)
or concordant antisense knockdown results in concomitant messenger
RNA reduction). In these cases, antisense oligonucleotides can be
targeted to overlapping or non-overlapping parts of the antisense
transcript resulting in its knockdown or sequestration. Coding well
non-coding antisense can be targeted in an identical manner and
that either category is capable of regulating the corresponding
sense transcripts--either in a concordant or disconcordant manner.
The strategies that are employed in identifying new
oligonucleotides for use against a target can be based on the
knockdown of antisense RNA transcripts by antisense
oligonucleotides or any other means of modulating the desired
target.
[0106] Strategy 1: In the case of discordant regulation, knocking
down the antisense transcript elevates the expression of the
conventional (sense) gene. Should that latter gene encode for a
known or putative drug target, then knockdown of its antisense
counterpart could conceivably mimic the action of a receptor
agonist or an enzyme stimulant.
[0107] Strategy 2: In the case of concordant regulation, one could
concomitantly knock down both antisense and sense transcripts and
thereby achieve synergistic reduction of the conventional (sense)
gene expression. If, for example, an antisense oligonucleotide is
used to achieve knockdown, then this strategy can be used to apply
one antisense oligonucleotide targeted to the sense transcript and
another antisense oligonucleotide to the corresponding antisense
transcript, or a single energetically symmetric antisense
oligonucleotide that simultaneously targets overlapping sense and
antisense transcripts.
[0108] According to the present invention, antisense compounds
include antisense oligonucleotides, ribozymes, external guide
sequence (EGS) oligonucleotides, siRNA compounds, single- or
double-stranded RNA interference (RNAi) compounds such as siRNA
compounds, and other oligomeric compounds which hybridize to at
least a portion of the target nucleic acid and modulate its
function. As such, they may be DNA, RNA, DNA-like, RNA-like; or
mixtures thereof, or may be mimetics of one or more of these. These
compounds may be single-stranded, doublestranded, circular or
hairpin oligomeric compounds and may contain structural elements
such as internal or terminal bulges, mismatches or loops. Antisense
compounds are routinely prepared linearly but can be joined or
otherwise prepared to be circular and/or branched. Antiscnse
compounds can include constructs such as, for example, two strands
hybridized to form a wholly or partially double-stranded compound
or a single strand with sufficient self-complementarity to allow
for hybridization and formation of fully or partially
double-stranded compound. The two strands can be linked internally
leaving free 3' or 5' termini or can be linked to form a continuous
hairpin structure or loop. The hairpin structure may contain an
overhang on either the 5' or 3' terminus producing an extension of
single stranded character. The double stranded compounds optionally
can include overhangs on the ends. Further modifications can
include conjugate groups attached to one of the termini, selected
nucleotide positions, sugar positions or to one of the
internucleoside linkages. Alternatively, the two strands can be
linked via a non-nucleic acid moiety or linker group. When formed
from only one strand, dsRNA can take the form of a
self-complementary hairpin-type molecule that doubles back on
itself to form a duplex. Thus, the dsRNAs can be fully or partially
double stranded. Specific modulation of gene expression can be
achieved by stable expression of dsRNA hairpins in transgenic cell
lines, however, in some embodiments, the gene expression or
function is up regulated. When formed from two strands, or a single
strand that takes the form of a self-complementary hairpin-type
molecule doubled back on itself to form a duplex, the two strands
(or duplex-forming regions of a single strand) are complementary
RNA strands that base pair in Watson-Crick fashion.
[0109] Once introduced to a system the compounds of the invention
may elicit the action of one or more enzymes or structural proteins
to effect cleavage or other modification of the target nucleic acid
or may work via occupancy-based mechanisms. In general, nucleic
acids (including oligonucleotides) may be described as "DNA-like"
(i.e., generally having one or more 2'-deoxy sugars and, generally,
T rather than U bases) or "RNA-like" (i.e., generally having one or
more 2'-hydroxyl or 2'-modified sugars and, generally U rather than
T bases). Nucleic acid helices can adopt more than one type of
structure, most commonly the A- and B-forms. It is believed that,
in general, oligonucleotides which have B-form-like structure are
"DNA-like" and those which have A-formlike structure are
"RNA-like." In some (chimeric) embodiments, an antisense compound
may contain both A- and B-form regions.
[0110] In an embodiment, the desired oligonucleotides or antisense
compounds, comprise at least one of: antisense RNA, antisense DNA,
chimeric antisense oligonucleotides, antisense oligonucleotides
comprising modified linkages, interference RNA (RNAi), short
interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small,
temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small
RNA-induced gene activation (RNAa); small activating RNAs (saRNAs),
or combinations thereof.
[0111] dsRNA can also activate gene expression, a mechanism that
has been termed "small RNA-induced gene activation" or RNAa. dsRNAs
targeting gene promoters induce potent transcriptional activation
of associated genes. RNAa was demonstrated in human cells using
synthetic dsRNAs, termed "small activating RNAs" (saRNAs). It is
currently not known whether RNAa is conserved in other
organisms.
[0112] Small double-stranded RNA (dsRNA), such as small interfering
RNA (siRNA) and microRNA (miRNA), have been found to be the trigger
of an evolutionary conserved mechanism known as RNA interference
(RNAi). RNAi invariably leads to gene silencing via remodeling
chromatin to thereby suppress transcription, degrading
complementary mRNA, or blocking protein translation. However, in
instances described in detail in the examples section which
follows, oligonucleotides are shown to increase the expression
and/or function of the Insulin Receptor Substrate 2 (IRS2)
polynucleotides and encoded products thereof. dsRNAs may also act
as small activating RNAs (saRNA). Without wishing to be bound by
theory, by targeting sequences in gene promoters, saRNAs would
induce target gene expression in a phenomenon referred to as
dsRNA-induced transcriptional activation (RNAa).
[0113] In a further embodiment, the "preferred target segments"
identified herein may be employed in a screen for additional
compounds that modulate the expression of Insulin Receptor
Substrate 2 (IRS2) or Transcription factor E3 (TFE3)
polynucleotides. "Modulators" are those compounds that decrease or
increase the expression of a nucleic acid molecule encoding IRS2
and which comprise at least a 5-nucleotide portion that is
complementary to a preferred target segment. The screening method
comprises the steps of contacting a preferred target segment of a
nucleic acid molecule encoding sense or natural nonsense
polynucleotides of IRS2 or TFE3 with one or more candidate
modulators, and selecting for one or more candidate modulators
which decrease or increase the expression of a nucleic acid
molecule encoding IRS2 polynucleotides, e.g. SEQ ID NOS: 4 to 9.
Once it is shown that the candidate modulator or modulators are
capable of modulating (e.g. either decreasing or increasing) the
expression of a nucleic acid molecule encoding IRS2
polynucleotides, the modulator may then be employed in further
investigative studies of the function of IRS2 polynucleotides, or
for use as a research, diagnostic, or therapeutic agent in
accordance with the present invention.
[0114] Targeting the natural antisense sequence preferably
modulates the function of the target gene. For example, the IRS2
gene (e.g. accession number NM.sub.--003749). In an embodiment, the
target is an antisense polynucleotide of the IRS2 or TFE3 gene. In
an embodiment, an antisense oligonucleotide targets sense and/or
natural antisense sequences of IRS2 or TFE3 polynucleotides (e.g.
accession number NM.sub.--003749) variants, alleles, isoforms,
homologs, mutants, derivatives, fragments and complementary
sequences thereto. Preferably the oligonucleotide is an antisense
molecule and the targets include coding and noncoding regions of
antisense and/or sense IRS2 or TFE3 polynucleotides.
[0115] The preferred target segments of the present invention may
be also be combined with their respective complementary antisense
compounds of the present invention to form stabilized
double-stranded (duplexed) oligonucleotides.
[0116] Such double stranded oligonucleotide moieties have been
shown in the art to modulate target expression and regulate
translation as well as RNA processing via an antisense mechanism.
Moreover, the double-stranded moieties may be subject to chemical
modifications. For example, such double-stranded moieties have been
shown to inhibit the target by the classical hybridization of
antisense strand of the duplex to the target, thereby triggering
enzymatic degradation of the target.
[0117] In an embodiment, an antisense oligonucleotide targets
Insulin Receptor Substrate 2 (IRS2) polynucleotides (e.g. accession
number NM.sub.--003749), variants, alleles, isoforms, homologs,
mutants, derivatives, fragments and complementary sequences
thereto. Preferably the oligonucleotide is an antisense
molecule.
[0118] In accordance with embodiments of the invention, the target
nucleic acid molecule is not limited to Insulin Receptor Substrate
2 (IRS2) and Transcription factor E3 (TFE3) alone but extends to
any of the isoforms, receptors, homologs and the like of IRS2 and
TFE3 molecules.
[0119] In an embodiment, an oligonucleotide targets a natural
antisense sequence of IRS2 or TFE3 polynucleotides, for example,
polynucleotides set forth as SEQ ID NOS: 2 and 3, and any variants,
alleles, homologs, mutants, derivatives, fragments and
complementary sequences thereto. Examples of antisense
oligonucleotides are set forth as SEQ ID NOS: 4 to 9.
[0120] In one embodiment, the oligonucleotides are complementary to
or bind to nucleic acid sequences of IRS2 or TFE3 antisense,
including without limitation noncoding sense and/or antisense
sequences associated with IRS2 or TFE3 polynucleotides and modulate
expression and/or function of IRS2 molecules.
[0121] In an embodiment, the oligonucleotides are complementary to
or bind to nucleic acid sequences of IRS2 or TFE3 natural
antisense, set forth as SEQ ID NOS: 2 and 3 and modulate expression
and/or function of IRS2 molecules.
[0122] In an embodiment, oligonucleotides comprise sequences of at
least 5 consecutive nucleotides of SEQ ID NOS: 4 to 9 and modulate
expression and/or function of IRS2 molecules.
[0123] The polynucleotide targets comprise IRS2 and TFE3, including
family members thereof, variants of IRS2 and TFE3; mutants of IRS2
and TFE3, including SNPs; noncoding sequences of IRS2 and TFE3;
alleles of IRS2 and TFE3; species variants, fragments and the like.
Preferably the oligonucleotide is an antisense molecule.
[0124] In an embodiment, the oligonucleotide targeting IRS2 or TFE3
polynucleotides, comprise: antisense RNA, interference RNA (RNAi),
short interfering RNA (siRNA); micro interfering RNA (miRNA); a
small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small
RNA-induced gene activation (RNAa); or, small activating RNA
(saRNA).
[0125] In an embodiment, targeting of IRS2 or TFE3 polynucleotides,
e.g. SEQ ID NOS: 2 and 3 modulate the expression or function of
these targets. In one embodiment, expression or function is
up-regulated as compared to a control. In an embodiment, expression
or function is down-regulated as compared to a control.
[0126] In an embodiment, antisense compounds comprise sequences set
forth as SEQ ID NOS: 4 to 9. These oligonucleotides can comprise
one or more modified nucleotides, shorter or longer fragments,
modified bonds and the like.
[0127] In an embodiment, SEQ ID NOS: 4 to 9 comprise one or more
LNA nucleotides.
[0128] The modulation of a desired target nucleic acid can be
carried out in several ways known in the art. For example,
antisense oligonucleotides, siRNA etc. Enzymatic nucleic acid
molecules (e.g., ribozymes) are nucleic acid molecules capable of
catalyzing one or more of a variety of reactions, including the
ability to repeatedly cleave other separate nucleic acid molecules
in a nucleotide base sequence-specific manner. Such enzymatic
nucleic acid molecules can be used, for example, to target
virtually any RNA transcript.
[0129] Because of their sequence-specificity, trans-cleaving
enzymatic nucleic acid molecules show promise as therapeutic agents
for human disease (Usman & McSwiggen, (1995) Ann. Rep. Med.
Chem. 30, 285-294; Christoffersen and Marr, (1995) J. Med. Chem.
38, 2023-2037). Enzymatic nucleic acid molecules can be designed to
cleave specific RNA targets within the background of cellular RNA.
Such a cleavage event renders the mRNA non-functional and abrogates
protein expression from that RNA. In this manner, synthesis of a
protein associated with a disease state can be selectively
inhibited.
[0130] In general, enzymatic nucleic acids with RNA cleaving
activity act by first binding to a target RNA. Such binding occurs
through the target binding portion of an enzymatic nucleic acid
which is held in close proximity to an enzymatic portion of the
molecule that acts to cleave the target RNA. Thus, the enzymatic
nucleic acid first recognizes and then binds a target RNA through
complementary base pairing, and once bound to the correct site,
acts enzymatically to cut the target RNA. Strategic cleavage of
such a target RNA will destroy its ability to direct synthesis of
an encoded protein. After an enzymatic nucleic acid has bound and
cleaved its RNA target, it is released from that RNA to search for
another target and can repeatedly bind and cleave new targets.
[0131] Several approaches such as in vitro selection (evolution)
strategies (Orgel, (1979) Proc. R. Soc. London, B 205, 435) have
been used to evolve new nucleic acid catalysts capable of
catalyzing a variety of reactions, such as cleavage and ligation of
phosphodiester linkages and amide linkages.
[0132] The development of ribozymes that are optimal for catalytic
activity would contribute significantly to any strategy that
employs RNA-cleaving ribozymes for the purpose of regulating gene
expression. The hammerhead ribozyme, for example, functions with a
catalytic rate (kcat) of about 1 min-1 in the presence of
saturating (10 mM) concentrations of Mg2+ cofactor. An artificial
"RNA ligase" ribozyme has been shown to catalyze the corresponding
self-modification reaction with a rate of about 100 min-1. In
addition, it is known that certain modified hammerhead ribozymes
that have substrate binding arms made of DNA catalyze RNA cleavage
with multiple turn-over rates that approach 100 min-1. Finally,
replacement of a specific residue within the catalytic core of the
hammerhead with certain nucleotide analogues gives modified
ribozymes that show as much as a 10-fold improvement in catalytic
rate. These findings demonstrate that ribozymes can promote
chemical transformations with catalytic rates that are
significantly greater than those displayed in vitro by most natural
self-cleaving ribozymes. It is then possible that the structures of
certain selfcleaving ribozymes may be optimized to give maximal
catalytic activity, or that entirely new RNA motifs can be made
that display significantly faster rates for RNA phosphodiester
cleavage.
[0133] Intermolecular cleavage of an RNA substrate by an RNA
catalyst that fits the "hammerhead" model was first shown in 1987
(Uhlenbeck, O. C. (1987) Nature, 328: 596-600). The RNA catalyst
was recovered and reacted with multiple RNA molecules,
demonstrating that it was truly catalytic.
[0134] Catalytic RNAs designed based on the "hammerhead" motif have
been used to cleave specific target sequences by making appropriate
base changes in the catalytic RNA to maintain necessary base
pairing with the target sequences. This has allowed use of the
catalytic RNA to cleave specific target sequences and indicates
that catalytic RNAs designed according to the "hammerhead" model
may possibly cleave specific substrate RNAs in vivo.
[0135] RNA interference (RNAi) has become a powerful tool for
modulating gene expression in mammals and mammalian cells. This
approach requires the delivery of small interfering RNA (siRNA)
either as RNA itself or as DNA, using an expression plasmid or
virus and the coding sequence for small hairpin RNAs that are
processed to siRNAs. This system enables efficient transport of the
pre-siRNAs to the cytoplasm where they are active and permit the
use of regulated and tissue specific promoters for gene
expression.
[0136] In an embodiment, an oligonucleotide or antisense compound
comprises an oligomer or polymer of ribonucleic acid (RNA) and/or
deoxyribonucleic acid (DNA), or a mimetic, chimera, analog or
homolog thereof. This term includes oligonucleotides composed of
naturally occurring nucleotides, sugars and covalent
internucleoside (backbone) linkages as well as oligonucleotides
having non-naturally occurring portions which function similarly.
Such modified or substituted oligonucleotides are often desired
over native forms because of desirable properties such as, for
example, enhanced cellular uptake, enhanced affinity for a target
nucleic acid and increased stability in the presence of
nucleases.
[0137] According to the present invention, the oligonucleotides or
"antisense compounds" include antisense oligonucleotides (e.g. RNA,
DNA, mimetic, chimera, analog or homolog thereof), ribozymes,
external guide sequence (EGS) oligonucleotides, siRNA compounds,
single- or double-stranded RNA interference (RNAi) compounds such
as siRNA compounds, saRNA, aRNA, and other oligomeric compounds
which hybridize to at least a portion of the target nucleic acid
and modulate its function. As such, they may be DNA, RNA, DNA-like,
RNA-like, or mixtures thereof, or may be mimetics of one or more of
these. These compounds may be single-stranded, double-stranded,
circular or hairpin oligomeric compounds and may contain structural
elements such as internal or terminal bulges, mismatches or loops.
Antisense compounds are routinely prepared linearly but can be
joined or otherwise prepared to be circular and/or branched.
Antisense compounds can include constructs such as, for example,
two strands hybridized to form a wholly or partially
double-stranded compound or a single strand with sufficient
self-complementarity allow for hybridization and formation of a
fully or partially double-stranded compound. The two strands can be
linked internally leaving free 3' or 5' termini or can be linked to
form a continuous hairpin structure or loop. The hairpin structure
may contain an overhang on either the 5' or 3' terminus producing
an extension of single stranded character. The double stranded
compounds optionally can include overhangs on the ends. Further
modifications can include conjugate groups attached to one of the
termini, selected nucleotide positions, sugar positions or to one
of the internucleoside linkages. Alternatively, the two strands can
be linked via a non-nucleic acid moiety or linker group. When
formed from only one strand, dsRNA can take the form of a
self-complementary hairpin-type molecule that doubles back on
itself to form a duplex. Thus, the dsRNAs can be fully or partially
double stranded. Specific modulation of gene expression can be
achieved by stable expression of dsRNA hairpins in transgenic cell
lines. When formed from two sounds, or a single strand that takes
the form of a self-complementary hairpin-type molecule doubled back
on itself to form a duplex, the two strands (or duplex-forming
regions of a single strand) are complementary RNA strands that base
pair in Watson-Crick fashion.
[0138] Once introduced to a system, the compounds of the invention
may elicit the action of one or more enzymes or structural proteins
to effect cleavage or other modification of the target nucleic acid
or may work via occupancy-based mechanisms. In general, nucleic
acids (including oligonucleotides) may be described as "DNA-like"
(i.e., generally having one or more 2'-deoxy sugars and, generally,
T rather than U bases) or "RNA-like" (i.e., generally having one or
more 2'-hydroxyl or 2'-modified sugars and, generally U rather than
T bases). Nucleic acid helices can adopt more than one type of
structure, most commonly the A- and B-forms. It is believed that,
in general, oligonucleotides which have B-form-like structure are
"DNA-like" and those which have A-formlike structure are
"RNA-like." In some (chimeric) embodiments, an antisense compound
may contain both A- and B-form regions.
[0139] The antisense compounds in accordance with this invention
can comprise an antisense portion from about 5 to about 80
nucleotides (i.e. from about 5 to about 80 linked nucleosides) in
length. This refers to the length of the antisense strand or
portion of the antisense compound. In other words, a
single-stranded antisense compound of the invention comprises from
5 to about 80 nucleotides, and a double-stranded antisense compound
of the invention (such as a dsRNA, for example) comprises a sense
and an antisense strand or portion of 5 to about 80 nucleotides in
length. One of ordinary skill in the art will appreciate that this
comprehends antisense portions of 5, 6, 7,8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 16, 37, 38, 39, 40,41,42, 43, 44, 45, 46, 47, 48,
49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,
66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80
nucleotides in length, or any range therewithin.
[0140] In one embodiment, the antisense compounds of the invention
have antisense portions of 10 to 50 nucleotides in length. One
having ordinary skill in the art will appreciate that this embodies
oligonucleotides having antisense portions of 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
49, or 50 nucleotides in length, or any range therewithin. In some
embodiments, the oligonucleotides are 15 nucleotides in length.
[0141] In one embodiment, the antisense or oligonucleotide
compounds of the invention have antisense portions of 12 or 13 to
30 nucleotides in length. One having ordinary skill in the art will
appreciate that this embodies antisense compounds having antisense
portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29 or 30 nucleotides in length, or any range
therewithin.
[0142] In an embodiment, the oligomeric compounds of the present
invention also include variants in which a different base is
present at one or more of the nucleotide positions in the compound.
For example, if the first nucleotide is an adenosine, variants may
be produced which contain thymidine, guanosine or cytidine at this
position. This may be done at any of the positions of the antisense
or dsRNA compounds. These compounds are then tested using the
methods described herein to determine their ability to inhibit
expression of a target nucleic acid.
[0143] In some embodiments, homology, sequence identity or
complementarity, between the antisense compound and target is from
about 40% to about 60%. In some embodiments, homology, sequence
identity or complementarity, is from about 60% to about 70%. In
some embodiments, homology, sequence identity or complementarity,
is from about 70% to about 80%. In some embodiments, homolopy,
sequence identity or complementarity, is from about 80% to about
90%. In some embodiments, homology, sequence identity or
complementarity, is about 90%, about 92%, about 94%, about 95%,
about 96%, about 97%, about 98%, about 99% or about 100%.
[0144] In an embodiment, the antisense oligonucleotides, such as
for example, nucleic acid molecules set forth in SEQ ID NOS: 2 to 9
comprise one or more substitutions or modifications. In one
embodiment, the nucleotides are substituted with locked nucleic
acids (LNA).
[0145] In an embodiment, the oligonucleotides target one or more
regions of the nucleic acid molecules sense and/or antisense of
coding and/or non-coding sequences associated with IRS2 or TFE3 and
the sequences set forth SEQ ID NOS: 1 to 3. The oligonucleotides
are also targeted to overlapping regions of SEQ ID NOS: 1 to 3.
[0146] Certain preferred oligonucleotides of this invention are
chimeric oligonucleotides. "Chimeric oligonucleotides" or
"chimeras," in the context of this invention, are oligonucleotides
which contain two or more chemically distinct regions, each made up
of at least one nucleotide. These oligenucleotides typically
contain at least one region of modified nucleotides that confers
one or more beneficial properties (such as, for example, increased
nuclease resistance, increased uptake into cells, increased binding
affinity for the target) and a region that is a substrate for
enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of
example, RNase H is a cellular endonuclease which cleaves the RNA
strand of an RNA:DNA duplex. Activation of RNase H, therefore,
results in cleavage of the RNA target, thereby greatly enhancing
the efficiency of antisense modulation of gene expression.
Consequently, comparable results can often be obtained with shorter
oligonucleotides when chimeric oligonucleotides are used, compared
to phosphorothioate deoxyoligonucleotides hybridizing to the same
target region. Cleavage of the RNA target can be routinely detected
by gel electrophoresis and, if necessary, associated nucleic acid
hybridization techniques known in the art. In one an embodiment, a
chimeric oligonucleotide comprises at least one region modified to
increase target binding affinity, and, usually, a region that acts
as a substrate for RNAse H. Affinity of an oligonucleotide for its
target (in this case, a nucleic acid encoding ras) is routinely
determined by measuring the Tm of an oligonucleotide/target pair,
which is the temperature at which the oligonucleotide and target
dissociate; dissociation is detected spectrophotometrically. The
higher the Tm, the greater is the affinity of the oligonucleotide
for the target.
[0147] Chimeric antisense compounds of the invention may be formed
as composite structures of two or more oligonucleotides, modified
oligonucleotides, oligonucleosides and/or oligonucleotides mimetics
as described above. Such; compounds have also been referred to in
the art as hybrids or gapmers. Representative United States patents
that teach the preparation of such hybrid structures comprise, but
are not limited to, U.S. Pat. Nos. 5,013,830; 5,149,797; 5,220,007,
5,256,775: 5,366,878; 5,403,711; 5,491,133: 5,565,350; 5,623,065;
5,652,355: 5,652,356; and 5,700,922, each of which is herein
incorporated by reference.
[0148] In an embodiment, the region of the oligonucleotide which is
modified comprises at least one nucleotide modified at the 2'
position of the sugar, most preferably a 2'-Oalkyl,
2'-O-alkyl-O-alkyl or 2'-fluoro-modified nucleotide. In other an
embodiment, RNA modifications include 2'-fluoro, 2'-amino and 2'
O-methyl modifications on the ribose of pyrimidines, abasic
residues or an inverted base at the 3' end of the RNA. Such
modifications are routinely incorporated into oligonucleotides and
these oligonucleotides have been shown to have a higher Tm (i.e.,
higher target binding affinity) than; 2'-deoxyoligonucleotides
against a given target. The effect of such increased affinity is to
greatly enhance RNAi oligonucleotide inhibition of gene expression.
RNAse H is a cellular endonuclease that cleaves the RNA strand of
RNA:DNA duplexes; activation of this enzyme therefore results in
cleavage of the RNA target, and thus can greatly enhance the
efficiency of RNAi inhibition. Cleavage of the RNA target can be
routinely demonstrated by gel electrophoresis. In an embodiment,
the chimeric oligonucleotide is also modified to enhance nuclease
resistance. Cells contain a variety of exo- and endo-nucleases
which can degrade nucleic acids. A number of nucleotide and
nucleoside modifications have been shown to make the
oligonucleotide into which they are incorporated more resistant to
nuclease digestion than the native oligodeoxynucleotide. Nuclease
resistance is routinely measured by incubating oligonucleotides
with cellular extracts or isolated nuclease solutions and measuring
the extent of intact oligonucleotide remaining over time, usually
by gel electrophoresis. Oligonucleotides which have been modified
to enhance their nuclease resistance survive intact for a longer
time than unmodified oligonucleotides. A variety of oligonucleotide
modifications have been demonstrated to enhance or confer nuclease
resistance. Oligonucleotides which contain at least one
phosphorothioate modification are presently more preferred. In some
cases, oligonucleotide modifications which enhance target binding
affinity are also, independently, able to enhance nuclease
resistance.
[0149] Specific examples of some preferred oligonucleotides
envisioned for this invention include those comprising modified
backbones, for example, phosphorothioates, phosphotriesters, methyl
phosphonates, short chain alkyl or cycloalkyl intersugar linkages
or short chain heteroatomic or heterocyclic intersugar linkages.
Most preferred are oligonucleotides with phosphorothioate backbones
and those with heteroatom backbones, particularly CH2-NH--O--CH2,
CH,--N(CH3)-O--CH2 [known as a methylene(methylimino) or MMI
backbone], CH2-O--N (CH3)-CH2, CH2-N(CH3)-N (CH3)-CH2 and
O--N(CH3)-CH2-CH2 backbones, wherein the native phosphodiester
backbone is represented as O--P--O--CH.sub.s). The amide backbones
disclosed by De Mesmacker et al. (1995) Acc. Chem. Res. 28:366-374
are also preferred. Also preferred are oligonucleotides having
morpholino backbone structures (Summerton and Weller, U.S. Pat. No.
5,034,506). In other an embodiment, such as the peptide nucleic
acid (PNA) backbone, the phosphodiester backbone of the
oligonucleotide is replaced with a polyamide backbone, the
nucleotides being bound directly or indirectly to the aza nitrogen
atoms of the polyamide backbone. Oligonucleotides may also comprise
one or more substituted sugar moieties. Preferred oligonucleotides
comprise one of the following at the 2' position: OH, SH, SCH3, F,
OCN, OCH3 OCH3, OCH3 O(CH2)n CH3, O(CH2)n NH2 or O(CH2)n CH3 where
n is from 1 to about 10; C1 to C10 lower alkyl, alkoxyalkoxy,
substituted lower alkyl, alkaryl or aralkyl; Cl; Br; CN; CF3; OCF3;
O--, S--, or N-alkyl O--, S--, or N-alkenyl; SOCH3; SO2 CH3; ONO2;
NO2; N3; NH2; heterocycloalkyl; heterocycloalkaryl;
aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving
group; a reporter group; an intercalator; a group for improving the
pharmacokinetic properties of an oligonucleotide; or a group for
improving the pharmacodynamic properties of an oligonucleotide and
other substituents having similar properties. A preferred
modification includes 2'-methoxyethoxy [2'-O-CH2 CH2 OCH3, also
known as 2'-O-(2-methoxyethyl)]. Other preferred modifications
include 2'-methoxy propoxy (2-O--CH3), 2'-propoxy (2'-OCH2 CH2CH3)
and 2'-fluoro (2'-F). Similar modifications may also be made at
other positions on the oligonucleotide; particularly the 3'
position of the sugar on the 3' terminal nucleotide and the 5'
position of 5' terminal nucleotide. Oligonucleotides may also have
sugar mimetics such as cyclobutyls in place of the pentofuranosyl
group.
[0150] Oligonucleotides may also include, additionally or
alternatively, nucleobase (often referred to in the art simply as
"base") modifications or substitutions. As used herein,
"unmodified" or "natural" nucleotides include adenine (A), guanine
(G), thymine (T), cytosine (C) and uracil (U). Modified nucleotides
include nucleotides found only infrequently or transiently in
natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me
pyrimidines, particularly 5-methylcytosine (also referred to as
5-methyl-2' deoxycytosine and often referred to in the art as
5-Me-C), 5-hydroxymethylcytosine (HMC), glycosyl HMC and
gentobiosyl HMC, as well as synthetic nucleotides, e.g.,
2-aminoadenine, 2-(methylamino)adenine, 2-(imidazolylalkyl)adenine,
2-(aminoalklyamino)adenine or other heterosubstituted
alkyladenines, 2-thiouracil, 2-thiothymine, 5-bromouracil,
5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N6
(6-aminohexyl)adenine and 2,6-diaminopurine, A "universal" base
known in the art, e.g., inosine, may be included. 5-Me-C
substitutions have been shown to increase nucleic acid duplex
stability by 0.6-1.2.degree. C. and are presently preferred base
substitutions.
[0151] Another modification of the oligonucleotides of the
invention involves chemically linking to the oligonucleotide one or
more moieties or conjugates which enhance the activity or cellular
uptake of the oligonucleotide. Such moieties include but are not
limited to lipid moieties such as a cholesterol moiety, a
cholesteryl moiety, an aliphatic chain, e.g., dodecandiol or
undecyl residues, a polyamine or a polyethylene glycol chain, or
Adamantane acetic acid. Oligonucleotides comprising Iipophilic
moieties, and methods for preparing such oligonucleotides are known
in the art, for example, U.S. Pat. No. 5,138,045, 5,218,105 and
5,459,255.
[0152] It is not necessary for all positions in a given
oligonucleotide to be uniformly modified, and in fact more than one
of the aforementioned modifications may be incorporated in a single
oligonucleotide or even at within a single nucleoside within an
oligonucleotide. The present invention also includes
oligonucleotides which are chimeric oligonucleotides as
hereinbefore defined.
[0153] In another embodiment, the nucleic acid molecule of the
present invention is conjugated with another moiety including but
not limited to abasic nucleotides, polyether, polyamine,
polyamides, peptides, carbohydrates, lipid, or polyhydrocarbon
compounds. Those skilled in the art will recognize that these
molecules can be linked to one or more of any nucleotides
comprising the nucleic acid molecule at several positions on the
sugar, base or phosphate group.
[0154] The oligonucleotides used in accordance with this invention
may be conveniently and routinely made through the well-known
technique of solid phase synthesis. Equipment for such synthesis is
sold by several vendors including Applied Biosystems. Any other
means for such synthesis may also be employed; the actual synthesis
of the oligonucleotides is well within the talents of one of
ordinary skill in the art. It is also well known to use similar
techniques to prepare other oligonucleotides such as the
phosphorothioates and alkylated derivatives. It is also well known
to use similar techniques and commercially available modified
amidites and controlled-pore glass (CPG) products such as biotin,
fluorescein, acridine or psoralen-modified amidites and/or CPG
(available from Glen Research, Sterling Va.) to synthesize
fluorescently labeled, biotinylated or other modified
oligonucleotides such as cholesterol-modified oligonucleotides.
[0155] In accordance with the invention, use of modifications such
as the use of LNA monomers to enhance the potency, specificity and
duration of action and broaden the routes of administration of
oligonucleotides comprised of current chemistries such as MOE, ANA,
FANA, PS etc. This can be achieved by substituting some of the
monomers in the current oligonucleotides by LNA monomers. The LNA
modified oligonucleotide may have a size similar to the parent
compound or may be larger or preferably smaller. It is preferred
that such LNA-modified oligonucleotides contain less than about
70%, more preferably less than about 60%, most preferably less than
about 50% LNA monomers and that their sizes are between about 5 and
25 nucleotides, more preferably between about 12 and 20
nucleotides.
[0156] Preferred modified oligonucleotide backbones comprise, but
not limited to, phosphorothioates, chiral phosphorothioates,
phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters,
methyl and other alkyl phosphonates comprising 3'alkylene
phosphonates and chiral phosphonates, phosphinates,
phosphoramidates comprising 3'-amino phosphoramidate and
aminoalkylphosphoramidates, thionophosphoramidates,
thionoalkylphosphonates, thionoalkylphosphotriesters, and
boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs
of these, and those having inverted polarity wherein the adjacent
pairs of nucleoside units are linked 5'-3' or 2'-5' to 5'-2'.
Various salts, mixed salts and free acid forms are also
included.
[0157] Representative United States patents that teach the
preparation of the above phosphorus containing linkages comprise,
but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863;
4,476,301, 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019;
5,278,302; 5,286,717; 5,321,131; 5,399,676: 5,405,939; 5,453,496;
5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306;
5,550,111; 5,563,253: 5,571,799; 5,587,361; and 5,625,050, each of
which is herein incorporated by reference.
[0158] Preferred modified oligonucleotide backbones that do not
include a phosphorus atom therein have backbones that are formed by
short chain alkyl or cycloalkyl internucleoside linkages, mixed
heteroatom and alkyl or cycloalkyl internucleoside linkages, or one
or more short chain heteroatomic or heterocyclic internucleoside
linkages. These comprise those having morpholino linkages (formed
in part from the sugar portion of a nucleoside); siloxane
backbones; sulfide, sulfoxide and sulfone backbones; formacetyI and
thioformacetyl backbones; methylene formacetyl and thioformacetyl
backbones; alkene containing backbones; sulfamate backbones;
methyleneimino and methylenehydrazino backbones; sulfonate and
sulfonamide backbones; amide backbones; and others having mixed N,
O, S and CH2 component parts.
[0159] Representative United States patents that teach the
preparation of the above oligonucleosides comprise, but are not
limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216,141; 5,235,033; 5264,562; 5,264,564; 5,405,938;
5,434,257; 5,466,677, 5,470,967, 5,489,677; 5,541,307; 5,561,225;
5,596,086; 5,603,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289:
5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677,437; and
5,677,439, each of which is herein incorporated by reference.
[0160] In other preferred oligonucleotide mimetics, both the sugar
and the internucleoside linkage, i.e., the backbone, of the
nucleotide units are replaced with novel groups. The base units are
maintained for hybridization with an appropriate nucleic acid
target compound. One such oligomeric compound, an oligonucleotide
mimetic that has been shown to have excellent hybridization
properties, is referred to as a peptide nucleic acid (PNA). In PNA
compounds, the sugar-backbone of an oligonucleotide is replaced
with an amide containing backbone, in particular an
aminoethylglycine backbone. The nucleobases are retained and are
bound directly or indirectly to aza nitrogen atoms of the amide
portion of the backbone. Representative United States patents that
teach the preparation of PNA compounds comprise, but are not
limited to U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, each
of which is herein incorporated by reference. Further teaching of
PNA compounds can be found in Nielsen, et al. (1991) Science 254,
1497-1500.
[0161] In an embodiment of the invention the oligonucleotides with
phosphorothioate backbones and oligonucleosides with heteroatom
backbones, and in particular
--CH2-NH--O--CH2-,--CH2-N(CH3)-O--CH.sub.2-known as a
methylene(methylimino) or MMI backbone,
--CH2-O--N(CH3)-CH2-,--CH2N(CH3)-N(CH3) CH2-and-O--N(CH3)-CH2-CH2-
wherein the native phosphodiester backbone is represented
as-O--P--O--CH2- of the above referenced U.S. Pat. No. 5,489,677,
and the amide backbones of the above referenced U.S. Pat. No.
5,602,240. Also preferred are oligonucleotides having morpholino
backbone structures of the above-referenced U.S. Pat. No.
5,034,506.
[0162] Modified oligonucleotides may also contain one or more
substituted sugar moieties. Preferred oligonucleotides comprise one
of the following at the 2' position: OH; F; O--, S--, or N-alkyl;
O--, S--, or N-alkenyl; O--, S-- or N-alkynyl or O alkyl-O-alkyl,
wherein the alkyl, alkenyl and alkynyl may be substituted or
unsubstituted C to CO alkyl or C2 to CO alkenyl and alkynyl.
Particularly preferred are O (CH2)n OmCH3, O(CH2)n,OCH3,
O(CH2)nNH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2nON(CH2)nCH3)2 where
n and m can be from 1 to about 10. Other preferred oligonucleotides
comprise one of the following at the 2' position: C to CO, (lower
alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or
O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2CH3,
ONO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl,
aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving
group, a reporter group, an intercalator, a group for improving the
pharmacokinetic properties of an oligonucleotide, or a group for
improving the pharmacodynamic properties of an oligonucleotide, and
other substituents having similar properties. A preferred
modification comprises 2'-methoxyethoxy (2'-O--CH2CH2OCH3, also
known as 2'-O-(2-methoxyethyl) or 2'-MOE) i.e., an alkoxyalkoxy
group. A further preferred modification comprises
2'-dimethylaminooxyethoxy, i.e., a O(CH2)2ON(CH3)2 group, also
known as 2'-DMAOE, as described in examples herein below, and
2'-dimethylaminoethoxyethoxy (also known in the art as
2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e.,
2'-O--CH2-O--CH2-N (CH2)2.
[0163] Other preferred modifications comprise 2'-methoxy (2'-O
CH3), 2'-aminopropoxy (2'-O CH2CH2CH2NH2) and 2'-fluoro (2'-F).
Similar modifications may also be made at other positions on the
oligonucleotide, particularly the 3' position of the sugar on the
3' terminal nucleotide or in 2'-5' linked oligonucleotides and the
5' position of 5' terminal nucleotide. Oligonucleotides may also
have sugar mimetics such as cyclobutyl moieties in place of the
pentofuranosyl sugar. Representative United States patents that
teach the preparation of such modified sugar structures comprise,
but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800;
5,319,080; 5,359,044; 5,393,878; 5,446;137; 5,466,786; 5,514,785;
5,519,114; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300;
5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and
5,700,920, each of which is herein incorporated by reference.
[0164] Oligonucleotides may also comprise nucleobase (often
referred to in the art simply as "base") modifications or
substitutions. As used herein, "unmodified" or "natural"
nucleotides comprise the purine bases adenine (A) and guanine (G),
and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
Modified nucleotides comprise other synthetic and natural
nucleotides such as 5-methylcytosine 5-hydroxymethyl cytosine,
xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl
derivatives of adenine and guanine, 2-propyl and other alkyl
derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and
2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and
cytosine, 6-azo uracil, cytosine and thymine, 5-uracil
(pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol,
8-hydroalkyl and other 8-substituted adenines and guanines, 5-halo
particularly 5-bromo, 5-trifluoromethyl and other 5-substituted
uracils and cytosines, 7-methylquanine and 7-methyladenine,
8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaguanine
and 3-deazaguanine and 3-deazaadenine.
[0165] Further, nucleotides comprise those disclosed in U.S. Pat.
No. 3,687,808, those disclosed in `The Concise Encyclopedia of
Polymer Science And Engineering`, pages 858-859, Kroschwitz, J. I.,
ed. John Wiley & Sons. 1990, those disclosed by Englisch et
al., `Angewandle Chemie, International Edition`, 1991, 30, page
613, and those disclosed by Sanghvi, Y. S., Chapter 15, `Antisense
Research and Applications`, pages 289-302, Crooke, S. T. and
Lebleu, B. ea., CRC Press, 1993. Certain of these nucleotides are
particularly useful for increasing the binding affinity of the
oligomeric compounds of the invention. These comprise 5-substituted
pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted
purines, comprising 2-aminopropyladenine, 5-propynyluracil and
5-propynylcytosine. 5-methylcytosine substitutions have been shown
to increase nucleic acid duplex stability by 0.6-1.2.degree. C.
(Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds, `Antisense
Research and Applications`, CRC Press, Boca Raton, 1993, pp.
276-278) and are presently preferred base substitutions, even more
particularly when combined with 2'-Omethoxyethyl sugar
modifications.
[0166] Representative United States patents that teach the
preparation of the above noted modified nucleotides as well as
other modified nucleotides comprise, but are not limited to U.S.
Pat. Nos. 3,687,808, as well as 4,845,205, 5,130,302; 5,134,066;
5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908;
5,507,177; 5,525,711; 5,552,540; 5,587,469; 5,596,091; 5,614,617;
5,750,692, and 5,681,941, each of which is herein incorporated by
reference.
[0167] Another modification of the oligonucleotides of the
invention involves chemically linking to the oligonucleotide one or
more moieties or conjugates, which enhance the activity, cellular
distribution, or cellular uptake of the oligonucleotide.
[0168] Such moieties comprise but are not limited to, lipid
moieties such as a cholesterol moiety, cholic acid, a thioether,
e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain,
e.g., dodecandiol or undecyl residues, a phospholipid, e.g.,
di-hexadecyl-rac-glycerol or triethylammonium
1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a
polyethylene glycol chain, or Adamantane acetic acid, a palmityl
moiety, or an octadecylamine or hexylamino-carbonyl-t
oxycholesterol moiety.
[0169] Representative United States patents that teach the
preparation of such oligonucleotides conjugates comprise, but are
not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882, 5,218,105;
5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731;
5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077;
5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735;
4,667,025; 4,762,779; 4,789,737; 4,874,941; 4,835,263; 4,876,335;
4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830;
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536;
5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203,
5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810;
5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923;
5,599,928 and 5,688,941, each of which is herein incorporated by
reference.
[0170] Drug discovery: The compounds of the present invention can
also be applied in the areas of drug discovery and target
validation. The present invention comprehends the use of the
compounds and preferred target segments identified herein in drug
discovery efforts to elucidate relationships that exist between
IRS2 or TFE3 polynucleotides and a disease state, phenotype, or
condition. These methods include detecting or modulating IRS2
polynucleotides comprising contacting a sample, tissue, cell, or
organism with the compounds of the present invention, measuring the
nucleic acid or protein level of IRS2 polynucleotides and/or a
related phenotypic or chemical endpoint at some time after
treatment, and optionally comparing the measured value to a
non-treated sample or sample treated with a further compound of the
invention. These methods can also be performed in parallel or in
combination with other experiments to determine the function of
unknown genes for the process of target validation or to determine
the validity of a particular gene product as a target for treatment
or prevention of a particular disease, condition, or phenotype.
Assessing Up-Regulation or Inhibition of Gene Expression:
[0171] Transfer of an exogenous nucleic acid into a host cell or
organism can be assessed by directly detecting the presence of the
nucleic acid in the cell or organism. Such detection can be
achieved by several methods well known in the art. For example, the
presence of the exogenous nucleic can be detected by Southern blot
or by a polymerase chain reaction (PCR) technique using primers
that specifically amplify nucleotide sequences associated with the
nucleic acid. Expression of the exogenous nucleic acids can also be
measured using conventional methods including gene expression
analysis. For instance, mRNA produced from an exogenous nucleic
acid can be detected and quantified using a Northern blot and
reverse transcription PCR (RT-PCR).
[0172] Expression of RNA from the exogenous nucleic acid can also
be detected by measuring an enzymatic activity or a reporter
protein activity. For example, antisense modulatory activity can be
measured indirectly as a decrease or increase in target nucleic
acid expression as an indication that the exogenous nucleic acid is
producing the effector RNA. Based on sequence conservation, primers
can be designed and used to amplify coding regions of the target
genes. Initially, the most highly expressed coding region from each
gene can be used to build a model control gene, although any coding
or non coding region can be used. Each control gene is assembled by
inserting each coding region between a reporter coding region and
its poly(A) signal. These plasmids would produce an mRNA with a
reporter gene in the upstream portion of the gene and a potential
RNAi target in the 3' non-coding region. The effectiveness of
individual antisense oligonucleotides would be assayed by
modulation of the reporter gene. Reporter genes useful in the
methods of the present invention include acetohydroxyacid synthase
(AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta
glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green
fluorescent protein (GFP), red fluorescent protein (RFP), yellow
fluorescent protein (YFP), cyan fluorescent protein (CFP),
horseradish peroxidase (HRP), luciferase (Luc), nopaline synthase
(NOS), octopine synthase (OCS), and derivatives thereof. Multiple
selectable markers are available that confer resistance to
ampicillin, bleomycin, chloramphenicol, gentamycin, hygromycin,
kanamycin, lincomycin, methotrexate, phosphinothricin, puromycin,
and tetracycline. Methods to determine modulation of a reporter
gene are well known in the art, and include, but are not limited
to, fluorometric methods (e.g. fluorescence spectroscopy,
Fluorescence Activated Cell Sorting (FACS), fluorescence
microscopy), antibiotic resistance determination.
[0173] IRS2 protein and mRNA expression can be assayed using
methods known to those of skill in the art and described elsewhere
herein. For example, immunoassays such as the ELISA can be used to
measure protein levels. IRS2 ELISA assay kits are available
commercially, e.g., from R&D Systems (Minneapolis, Minn.).
[0174] In embodiments, IRS2 expression (e.g., mRNA or protein) in a
sample (e.g., cells or tissues in vivo or in vitro) treated using
an antisense oligonucleotide of the invention is evaluated by
comparison with IRS2 expression in a control sample. For example,
expression of the protein or nucleic acid can be compared using
methods known to those of skill in the art with that in a
mock-treated or untreated sample. Alternatively, comparison with a
sample treated with a control antisense oligonucleotide (e.g., one
having an altered or different sequence) can be made depending on
the information desired. In another embodiment, a difference in the
expression or the IRS2 protein or nucleic acid in a treated vs. an
untreated sample can be compared with the difference in expression
of a different nucleic acid (including any standard deemed
appropriate by the researcher, e.g., a housekeeping gene) in a
treated sample vs. an untreated sample.
[0175] Observed differences can be expressed as desired, e.g., in
the form of a ratio or fraction, for use in a comparison with
control. In embodiments, the level of IRS2 mRNA or protein, in a
sample treated with an antisense oligonucleotide of the present
invention, is increased or decreased by about 1.25-fold to about
10-fold or more relative to an untreated sample or a sample treated
with a control nucleic acid. In embodiments, the level of IRS2 mRNA
or protein is increased or decreased by at least about 1.25-fold,
at least about 1.3-fold, at least about 1.4-fold, at least about
1.5-fold, at least about 1.6-fold, at least about 1.7-fold, at
least about 1.8-fold, at least about 2-fold, at least about
2.5-fold, at least about 3-fold, at least about 3.5-fold, at least
about 4-fold, at least about 4.5-fold, at least about 5-fold, at
least about 5.5-fold, at least about 6-fold, at least about
6.5-fold, at least about 7-fold, at least about 7.5-fold, at least
about 8-fold, at least about 8.5-fold, at least about 9-fold, at
least about 9.5-fold, or at least about 10-fold or more.
Kits, Research Reagents, Diagnostics, and Therapeutics
[0176] The compounds of the present invention can be utilized for
diagnostics, therapeutics, and prophylaxis, and as research
reagents and components of kits. Furthermore, antisense
oligonucleotides, which are able to inhibit gene expression with
exquisite specificity, are often used by those of ordinary skill to
elucidate the function of particular genes or to distinguish
between functions of various members of a biological pathway.
[0177] For use in kits and diagnostics and in various biological
systems, the compounds of the present invention, either alone or in
combination with other compounds or therapeutics, are useful as
tools in differential and/or combinatorial analyses to elucidate
expression patterns of a portion or the entire complement of genes
expressed within cells and tissues.
[0178] As used herein the term "biological system" or "system" is
defined as any organism, cell, cell culture or tissue that
expresses, or is made competent to express products of the IRS2 and
TFE3 genes. These include, but are not limited to, humans,
transgenic animals, cells, cell cultures, tissues, xenografts,
transplants and combinations thereof.
[0179] As one non limiting example, expression patterns within
cells or tissues treated with one or more antisense compounds are
compared to control cells or tissues not treated with antisense
compounds and the patterns produced are analyzed for differential
levels of gene expression as they pertain, for example, to disease
association, signaling pathway, cellular localization, expression
level, size, structure or function of the genes examined. These
analyses can be performed on stimulated or unstimulated cells and
in the presence or absence of other compounds that affect
expression patterns.
[0180] Examples of methods of gene expression analysis known in the
art include DNA arrays or microarrays, SAGE (serial analysis of
gene expression), READS (restriction enzyme amplification of
digested cDNAs). TOGA (total gene expression analysis), protein
arrays and proteomics, expressed sequence tag (EST) sequencing,
subtractive RNA fingerprinting (SuRF), subtractive cloning,
differential display (DD), comparative genomic hybridization FISH
(fluorescent in situ hybridization) techniques and mass
spectrometry methods.
[0181] The compounds of the invention are useful for research and
diagnostics, because these compounds hybridize to nucleic acids
encoding IRS2 or TFE3. For example, oligonucleotides that hybridize
with such efficiency and under such conditions as disclosed herein
as to be effective IRS2 or TFE3 modulators are effective primers or
probes under conditions favoring gene amplification or detection,
respectively. These primers and probes are useful in methods
requiring the specific detection of nucleic acid molecules encoding
IRS2 or TFE3 and in the amplification of said nucleic acid
molecules for detection or for use in further studies of IRS2 or
TFE3. Hybridization of the antisense oligonucleotides, particularly
the primers and probes, of the invention with a nucleic acid
encoding IRS2 or TFE3 can be detected by means known in the art.
Such means may include conjugation of an enzyme to the
oligonucleotide, radiolabeling of the oligonucleotide, or any other
suitable detection means. Kits using such detection means for
detecting the level of IRS2 or TFE3 in a sample may also be
prepared.
[0182] The specificity and sensitivity of antisense are also
harnessed by those of skill in the art for therapeutic uses.
Antisense compounds have been employed as therapeutic moieties in
the treatment of disease states in animals, including humans.
Antisense oligonucleotide drugs have been safely and effectively
administered to humans and numerous clinical trials are presently
underway. It is thus established that antisense compounds can be
useful therapeutic modalities that can be configured to be useful
in treatment regimes for the treatment of cells, tissues and
animals, especially humans.
[0183] For therapeutics, an animal, preferably a human, suspected
of having a disease or disorder which can be treated by modulating
the expression of IRS2 or TFE3 polynucleotides is treated by
administering antisense compounds in accordance with this
invention. For example, in one non-limiting embodiment, the methods
comprise the step of administering to the animal in need of
treatment, a therapeutically effective amount of IRS2 or TFE3
modulator. The IRS2 or TFE3 modulators of the present invention
effectively modulate the activity of the IRS2 or modulate the
expression of the IRS2 protein. In one embodiment, the activity or
expression of IRS2 in an animal is inhibited by about 10% as
compared to a control. Preferably, the activity or expression of
IRS2 in an animal is inhibited by about 30%. More preferably, the
activity or expression of IRS2 in an animal is inhibited by 50% or
more. Thus, the oligomeric compounds modulate expression of IRS2
mRN A by at least 10%, by at least 50%, by at least 25%, by at
least 30%, by at least 40%, by at least 50%, by at least 60%, by at
least 70%, by at least 75%, by at least 80%, by at least 85%, by at
least 90%, by at least 95%, by at least 98%, by at least 99%, or by
100% as compared to a control.
[0184] In one embodiment, the activity or expression of Insulin
Receptor Substrate 2 (IRS2) and/or in an animal is increased by
about 10% as compared to a control. Preferably, the activity or
expression of IRS2 in an animal is increased by about 30%. More
preferably, the activity or expression of IRS2 in an animal is
increased by 50% or more. Thus, the oligomeric compounds modulate
expression of IRS2 mRNA by at least 10%, by at least 50%, by at
least 25%, by at least 30%, by a least 40%, by at least 50%, by at
least 60%, by at least 70%, by at least 75%, by at least 80%, by at
least 85%, by at least 90%, by at least 95%, by at least 98%, by at
least 99%, or by 100% as compared to a control.
[0185] For example, the reduction of the expression of Insulin
Receptor Substrate 2 (IRS2) may be measured in serum, blood,
adipose tissue, liver or any other body fluid, tissue or organ of
the animal. Preferably, the cells contained within said fluids,
tissues or organs being analyzed contain a nucleic acid molecule
encoding IRS2 peptides and/or the IRS2 protein itself.
[0186] The compounds of the invention can be utilized in
pharmaceutical compositions by adding an effective amount of a
compound to a suitable pharmaceutically acceptable diluent or
carrier. Use of the compounds and methods of the invention may also
be useful prophylactically.
Conjugates
[0187] Another modification of the oligonucleotides of the
invention involves chemically linking to the oligonucleotide one or
more moieties or conjugates that enhance the activity, cellular
distribution or cellular uptake of the oligomucleotide. These
moieties or conjugates can include conjugate groups covalently
bound to functional groups such as primary or secondary hydroxyl
groups. Conjugate groups of the invention include intercalators,
reporter molecules, polyamines, polyamides, polyethylene glycols,
polyethers, groups that enhance the pharmacodynamic properties of
oligomers, and groups that enhance the pharmacokinetic properties
of oligomers. Typical conjugate groups include cholesterols,
lipids, phospholipids, biotin, phenazine, folate, phenanthridine,
anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and
dyes. Groups that enhance the pharmacodynamic properties, in the
context of this invention, include groups that improve uptake,
enhance resistance to degradation, and/or strengthen
sequence-specific hybridization with the target nucleic acid.
Groups that enhance the pharmacokinetic properties, in the context
of this invention, include groups that improve uptake,
distribution, metabolism or excretion of the compounds of the
present invention. Representative conjugate groups are disclosed in
International Patent Application No. PCT/US92/09196, filed. Oct.
23, 1992, and U.S. Pat. No. 6,287,860, which we incorporated herein
by reference. Conjugate moieties include, but are not limited to,
lipid moieties such as a cholesterol moiety, cholic acid, a
thioether, e.g., hexyl-5-tritylthiol, a thiocholesterol, an
aliphatic chain, e.g., dodecandiol or undecyl residues, a
phospholipid, e.g., di-hexadecyl-rac-gycerol or triethylammonium
1,2-di-O-hexadecyl-rac-glycero-3-Hphosphonate, a polyamine or a
polyethylene glycol chain, or Adamantane acetic acid, a palmityl
moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol
moiety. Oligonucleotides of the invention may also be conjugated to
active drug substances, for example, aspirin, warfarin,
phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen,
(S)-(+)-pranoprofen, carprofen, dansylsarcosine,
2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a
benzothiadiazide, chlorothiazide, a diazepine, indomethicin, a
barbiturate, cephalosporin, a sulfa drug, an antidiabetic, an
antibacterial or an antibiotic.
[0188] Representative United States patents that teach the
preparation of such oligonucleotides conjugates include, but are
not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105,
5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731;
5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077;
5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735;
4,667,025; 4,762,779: 4,789,737; 4,824,941, 4,835,363; 4,876,335;
4,904,582; 4,958,013; 5,082,830; 5,112,963: 5,214,136; 5,082,830;
5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536;
5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,773; 5,416,303,
5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810;
5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923;
5,599,928 and 5,688,941.
Formulations
[0189] The compounds of the invention may also be admixed,
encapsulated, conjugated or otherwise associated with other
molecules, molecule structures or mixtures of compounds, as for
example, liposomes, receptor-targeted molecules, oral, rectal,
topical or other formulations, for assisting in uptake,
distribution and/or absorption. Representative United States
patents that teach the preparation of such uptake, distribution
and/or absorption-assisting formulations include, but are not
limited to U.S. Pat. Nos. 5,108,921; 5,354,844; 5,416,016;
5,459,127; 5,521,291; 5,543,165; 5,547,932, 5,583,020; 5,591,721;
4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170;
5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978, 5,462,854;
5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948;
5,580,575; and 5,595,756, each of which is herein incorporated by
reference.
[0190] Although, the antisense oligonucleotides do not need to be
administered in the context of a vector in order to modulate a
target expression and/or function embodiments of the invention
relates to expression vector constructs for the expression of
antisense oligonucleotides, comprising promoters, hybrid promoter
gene sequences and possess a strong constitutive promoter activity,
or a promoter activity which can be induced in the desired
case.
[0191] In an embodiment, invention practice involves administering
at least one of the foregoing antisense oligonucleotides with a
suitable nucleic acid delivery system. In one embodiment, that
system includes a non-viral vector operably linked to the
polynucleotide. Examples of such nonviral vectors include the
oligonucleotide alone (e.g. any one or more of SEQ ID NOS: 4 to 9)
or in combination with a suitable protein, polysaccharide or lipid
formulation.
[0192] Additionally suitable nucleic acid delivery systems include
viral vector, typically sequence from at least one of an
adenovirus, adenovirus-associated virus (AAV), helper-dependent
adenovirus, retrovirus, or hemagglutinatin virus of Japan-liposome
(HVJ) complex. Preferably, the viral vector comprises a strong
eukaryotic promoter operably linked to the polynucleotide e.g., a
cytomegalovirus (CMV) promoter.
[0193] Additionally preferred vectors include viral vectors, fusion
proteins and chemical conjugates. Retroviral vectors include
Moloney murine leukemia viruses and HIV-based viruses. One
preferred HIV-based viral vector comprises at least two vectors
wherein the gag and pol genes are from an HIV genome and the env
acne is from another virus. DNA viral vectors are preferred. These
vectors include pox vectors such as orthopox or avipox vectors,
herpesvirus vectors such as a herpes simplex I virus (HSV) vector,
Adenovirus Vectors and Adeno-associated Virus Vectors.
[0194] The antisense compounds of the invention encompass any
pharmaceutically acceptable salts, esters, or salts of such esters,
or any other compound which, upon administration to an animal,
including a human, is capable of providing (directly or indirectly)
the biologically active metabolite or residue thereof.
[0195] The term "pharmaceutically acceptable salts" refers to
physiologically and pharmaceutically acceptable salts of the
compounds of the invention: i.e., salts that retain the desired
biological activity of the parent compound and do not impart
undesired toxicological effects thereto. For oligonucleotides,
preferred examples of pharmaceutically acceptable salts and their
uses are further described, in U.S. Pat. No. 6,287,860, which is
incorporated herein by reference.
[0196] The present invention also includes pharmaceutical
compositions and formulations that include the antisense compounds
of the invention. The pharmaceutical compositions of the present
invention may be administered in a number of ways depending upon
whether local or systemic treatment is desired and upon the area to
be treated. Administration may be topical (including ophthalmic and
to mucous membranes including vaginal and rectal delivery),
pulmonary, e.g., by inhalation or insufflation of powders or
aerosols, including by nebulizer; intratracheal, intranasal,
epidermal and transdermal), oral or parenteral. Parenteral
administration includes intravenous, intraarterial, subcutaneous,
intraperitoneal or intramuscular injection or infusion; or
intracranial, e.g., intrathecal or intraventricular,
administration.
[0197] For treating tissues in the central nervous system,
administration can be made by, e.g., injection or infusion into the
cerebrospinal fluid. Administration of antisense RNA into
cerebrospinal fluid is described, e.g., in U.S. Pat. App. Pub. No.
2007/0117772, "Methods for slowing familial ALS disease
progression," incorporated herein by reference in its entirety.
[0198] When it is intended that the antisense oligonucleotide of
the present invention be administered to cells in the central
nervous system, administration can be with one or more agents
capable of promoting penetration of the subject antisense
oligonucleotide across the blood-brain barrier. Injection can be
made, e.g., in the enterhinal cortex or hippocampus. Delivery of
neurotrophic factors by administration of an adenovirus vector to
motor neurons in muscle tissue is described in, e.g., U.S. Pat. No.
6,632,427, "Adenoviral-vector-mediated gene transfer into medullary
motor neurons," incorporated herein by reference. Delivery of
vectors directly to the brain, e.g., the striatum, the thalamus,
the hippocampus, or the substantia nigra, is known in the art and
described, e.g., in U.S. Pat. No. 6,756,523, "Adenovirus vector,
for the transfer of foreign genes into cells of the central nervous
system particularly in brain," incorporated herein by reference.
Administration can be rapid as by injection or made over a period
of time as by slow infusion or administration of slow release
formulations.
[0199] The subject antisense oligonucleotides can also be linked or
conjugated with agents that provide desirable pharmaceutical or
pharmacodynamic properties. For example, the antisense
oligonucleotide can be coupled to any substance, known in the art
to promote penetration or transport across the blood-brain barrier,
such as an antibody to the transferrin receptor, and administered
by intravenous injection. The antisense compound can be linked with
a viral vector, for example, that makes the antisense compound more
effective and/or increases the transport of the antisense compound
across the blood-brain barrier. Osmotic blood brain barrier
disruption can also be accomplished by, e.g., infusion of sugars
including, but not limited to, meso erythritol, D(+) galactose,
D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose,
D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose,
cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+)
melibiose, D(+) ribose, adonitol, D(+) arabitol, L(-) arabitol,
D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-)
lyxose, or amino acids including, but not limited to, glutamine,
lysine, arginine, asparagine, aspartic acid, cysteine, glutamic
acid, glycine, histidine, leucine, methionine, phenylalanine,
proline, serine, threonine, tyrosine, valine, and taurine. Methods
and materials for enhancing blood brain barrier penetration are
described, e.g., in U.S. Pat. No. 4,866,042, "Method for the
delivery of genetic material across the blood brain barrier." U.S.
Pat. No. 6,294,520, "Material for passage through the blood-brain
barrier," and U.S. Pat. No. 6,936,589, "Parenteral delivery
systems," all incorporated herein by reference in their
entirety.
[0200] The subject antisense compounds may be admixed,
encapsulated, conjugated or otherwise associated with other
molecules, molecule structures or mixtures of compounds, for
example, liposomes, receptor-targeted molecules, oral, rectal,
topical or other formulations, for assisting in uptake,
distribution and/or absorption. For example, cationic lipids may be
included in the formulation to facilitate oligonucleotide uptake.
One such composition shown to facilitate uptake is LIPOFECTIN
(available from GIBCO-BRL, Bethesda, Md.).
[0201] Oligonucleotides with at least one 2'-O-methoxyethyl
modification are believed to be particularly useful for oral
administration. Pharmaceutical compositions and formulations for
topical administration may include transdermal patches, ointments,
lotions, creams, gels, drops, suppositories, sprays, liquids and
powders. Conventional pharmaceutical carriers, aqueous, powder or
oily bases, thickeners and the like may be necessary or desirable.
Coated condoms, gloves and the like may also be useful.
[0202] The pharmaceutical formulations of the present invention,
which may conveniently be presented in unit dosage from, may be
prepared according to conventional techniques well known in the
pharmaceutical industry. Such techniques include the step of
bringing into association the active ingredients with the
pharmaceutical carrier(s) or excipient(s). In general, the
formulations are prepared by uniformly and intimately bringing into
association the active ingredients with liquid carriers or finely
divided solid carriers or both, and then, if necessary, shaping the
product.
[0203] The compositions of the present invention may be formulated
into any of many possible dosage forms such as, but not hunted to,
tablets, capsules, gel capsules, liquid syrups, soft gels,
suppositories, and enemas. The compositions of the present
invention may also be formulated as suspensions in aqueous,
non-aqueous or mixed media. Aqueous suspensions may further contain
substances that increase the viscosity of the suspension including,
for example, sodium carboxymethylcellulose, sorbitol and/or
dextran. The suspension may also contain stabilizers.
[0204] Pharmaceutical compositions of the present invention
include, but are not limited to, solutions, emulsions, foams and
liposome-containing formulations. The pharmaceutical compositions
and formulations of the present invention may comprise one or more
penetration enhancers, carriers, excipients or other active or
inactive ingredients.
[0205] Emulsions are typically heterogeneous systems of one liquid
dispersed in another in the form of droplets usually exceeding 0.1
.mu.m in diameter. Emulsions may contain additional components in
addition to the dispersed phases and the active drug that may be
present as a solution in either the aqueous phase, oily phase or
itself as a separate phase. Microemulsions are included as an
embodiment of the present invention. Emulsions and their uses are
well known in the art and are further described in U.S. Pat. No.
6,287,860.
[0206] Formulations of the present invention include liposomal
formulations. As used in the present invention, the term "liposome"
means a vesicle composed of amphiphilic lipids arranged in a
spherical bilayer or bilayers. Liposomes are unilamellar or
multilamellar vesicles which have a membrane formed from a
lipophilic material and an aqueous interior that contains the
composition to be delivered. Cationic liposomes are positively
charged liposomes that are believed to interact with negatively
charged DNA molecules to form a stable complex. Liposomes that are
pH-sensitive or negatively-charged are believed to entrap DNA
rather than complex with it. Both cationic and noncationic
liposomes have been used to deliver DNA to cells.
[0207] Liposomes also include "sterically stabilized" liposomes, a
term which, as used herein, refers to liposomes comprising one or
more specialized lipids. When incorporated into liposomes, these
specialized lipids result in liposomes with enhanced circulation
lifetimes relative to liposomeslacking such specialized lipids.
Examples of sterically stabilized liposomes are those in which part
of the vesicle-forming lipid portion of the liposome comprises one
or more glycolipids or is derivatized with one or more hydrophilic
polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and
their uses are further described in U.S. Pat. No. 6,287,860.
[0208] The pharmaceutical formulations and compositions of the
present invention may also include surfactants. The use of
surfactants in drug products, formulations and in emulsions is well
known in the art. Surfactants and their uses are further described
in U.S. Pat. No. 6,287,860, which is incorporated herein by
reference.
[0209] In one embodiment, the present invention employs various
penetration enhancers to effect the efficient delivery of nucleic
acids, particularly oligonucleotides. In addition to aiding the
diffusion of non-lipophilic drugs across cell membranes,
penetration enhancers also enhance the permeability of lipophilic
drugs. Penetration enhancers may be classified as belonging to one
of five broad categories, i.e., surfactants, fatty acids, bile
salts, chelating agents, and non-chelating nonsurfactants.
Penetration enhancers and their uses are further described in U.S.
Pat. No. 6,287,860, which is incorporated herein by reference.
[0210] One of skill in the art will recognize that formulations are
routinely designed according to their intended use, i.e. route of
administration.
[0211] Preferred formulations for topical administration include
those in which the oligonucleotides of the invention are in
admixture with a topical delivery agent such as lipids, liposomes,
fatty acids, fatty acid esters, steroids, chelating agents and
surfactants. Preferred lipids and liposomes include neutral (e.g.
dioleoyl-phosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl
choline DMPC, distearolyphosphatidyl choline) negative (e.g.
dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g.
dioleoyltetramethylaminopropyl DOTAP and dioleoyl-phosphatidyl
ethanolamine DOTMA).
[0212] For topical or other administration, oligonucleotides of the
invention may be encapsulated within liposomes or may form
complexes thereto, in particular to cationic liposomes.
Alternatively, oligonucleotides may be complexed to lipids, in
particular to cationic lipids. Preferred fatty acids and esters,
pharmaceutically acceptable salts thereof, and their uses are
further described in U.S. Pat. No. 6,287,860.
[0213] Compositions and formulations for oral administration
include powders or granules, microparticulates, nanoparticulates,
suspensions or solutions in water or non-aqueous media, capsules,
gel capsules, sachets, tablets or minitablets. Thickeners,
flavoring agents, diluents, emulsifiers, dispersing aids or binders
may be desirable. Preferred oral formulations are those in which
oligonucleotides of the invention are administered in conjunction
with one or more penetration enhancers surfactants and chelators.
Preferred surfactants include fatty acids and/or esters or salts
thereof, bile acids and/or salts thereof. Preferred bile
acids/salts and fatty acids and their uses are further described in
U.S. Pat. No. 6,287,860, which is incorporated herein by reference.
Also preferred are combinations of penetration enhancers, for
example, fatty acids/salts in combination with bile acids/salts. A
particularly preferred combination is the sodium salt of lauric
acid, capric acid and UDCA. Further penetration enhancers include
polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether.
Oligonucleotides of the invention may be delivered orally, in
granular form including sprayed dried particles, or complexed to
form micro or nanoparticles. Oligonucleotide complexing agents and
their uses are further described in U.S. Pat. No. 6,287,860, which
is incorporated herein by reference.
[0214] Compositions and formulations for parenteral, intrathecal or
intraventricular administration may include sterile aqueous
solutions that may also contain buffers, diluents and other
suitable additives such as, but not limited to, penetration
enhancers, carrier compounds and other pharmaceutically acceptable
carriers or excipients.
[0215] Certain embodiments of the invention provide pharmaceutical
compositions containing one or more oligomeric compounds and one or
more other chemotherapeutic agents that function by a non-antisense
mechanism. Examples of such chemotherapeutic agents include but are
not limited to cancer chemotherapeutic drugs such as daunorubicin,
daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin,
esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine
arabinoside, bischloroethyl-nitrosurea, busulfan, mitomycin C,
actinomycin D, mithramycin, prednisone, hydroxyprogesterone,
testosterone, tamoxifen, dacarbazine, procarbazine,
hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine,
chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards,
melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine,
cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin,
4-hydroxyperoxycyclo-phosphoramide, 5-fluororacil (5-FU),
5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine,
taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate,
irinotecan, topotecan, gemcitabine, teniposide, cisplatin and
diethylstilbestrol (DES). When used with the compounds of the
invention, such chemotherapeutic agents may be used individually
(e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and
oligonucleotide for a period of time followed by MTX and
oligonucleotide), or in combination with one or more other such
chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or
5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs,
including but not limited to nonsteroidal anti-inflammatory drugs
and corticosteroids, and antiviral drugs, including but not limited
to ribivirin, vidarabine, acyclovir and ganciclovir, may also be
combined in compositions of the invention. Combinations of
antisense compounds and other non-antisense drugs are also within
the scope of this invention. Two or more combined compounds may be
used together or sequentially.
[0216] In another related embodiment, compositions of the invention
may contain one or more antisense compounds, particularly
oligonucleotides, targeted to a first nucleic acid and one or more
additional antisense compounds targeted to a second nucleic acid
target. For example, the first target may be a particular antiscnse
sequence of IRS2 or TFE3, and the second target may be a region
from another nucleotide sequence. Alternatively, compositions of
the invention may contain two or more antisense compounds targeted
to different regions of the same IRS2 or TFE3 nucleic acid target.
Numerous examples of antisense compounds are illustrated herein and
others may be selected from among suitable compounds known in the
art. Two or more combined compounds may be used together or
sequentially.
Dosing:
[0217] The formulation of therapeutic compositions and their
subsequent administration (dosing) is believed to be within the
skill of those in the art. Dosing is dependent on severity and
responsiveness of the disease state to be treated, with the course
of treatment lasting from several days to several months, or until
a cure is effected or a diminution of the disease state is
achieved. Optimal dosing schedules can be calculated from
measurements of drug accumulation in the body of the patient.
Persons of ordinary skill can easily determine optimum dosages,
dosing methodologies and repetition rates. Optimum dosages may vary
depending on the relative potency of individual oligonucleotides,
and can generally be estimated based on EC50s found to be effective
in vitro and in vivo animal models. In general, dosage is from 0.01
.mu.g to 100 g per kg of body weight, and may be given once or more
daily, weekly, monthly or yearly, or even once every 2 to 20 years.
Persons of ordinary skill in the art can easily estimate repetition
rates for dosing based on measured residence times and
concentrations of the drug in bodily fluids or tissues. Following
successful treatment, it may be desirable to have the patient
undergo maintenance therapy to prevent the recurrence of the
disease state, wherein the oligonucleotide is administered in
maintenance doses, ranging from 0.01 .mu.g to 100 g per kg of body
weight, once or more daily, to once every 20 years.
[0218] In embodiments, a patient is treated with a dosage of drug
that is at least about 1, at least about 2, at least about 3, at
least about 4, at least about 5, at least about 6, at least about
7, at least about 8, at least about 9, at least about 10, at least
about 15, at least about 20, at least about 25, at least about 30,
at least about 35, at least about 40, at least about 45, at least
about 50, at least about 60, at least about 70, at least about 80,
at least about 90, or at least about 100 mg/kg body weight. Certain
injected dosages of antisense oligonucleotides are described, e.g.,
in U.S. Pat. No. 7,563,884, "Antisense modulation of PTP1B
expression," incorporated herein by reference in its entirety.
[0219] While various embodiments of the present invention have been
described above, it should be understood that they have been
presented by way of example only, and not limitation. Numerous
changes to the disclosed embodiments can be made in accordance with
the disclosure herein without departing from the spirit or scope of
the invention. Thus, the breadth and scope of the present invention
should not be limited by any of the above described
embodiments.
[0220] All documents mentioned herein are incorporated herein by
reference. All publications and patent documents cited in this
application are incorporated by reference for all purposes to the
same extent as if each individual publication or patent document
were so individually denoted. By their citation of various
references in this document, Applicants do not admit any particular
reference is "prior art" to their invention. Embodiments of
inventive compositions and methods are illustrated in the following
examples.
EXAMPLES
[0221] The following non-limiting Examples serve to illustrate
selected embodiments of the invention. It will be appreciated that
variations in proportions and alternatives in elements of the
components shown will be apparent to those skilled in the art and
are within the scope of embodiments of the present invention.
Example 1
Design of Antisense Oligonucleotide Specific for a Nucleic Acid
Molecule Antisense to and/or Sense Strand of Insulin Receptor
Substrate 2 (IRS2) or Transcription factor E3 (TFE3)
Polynucleotide
[0222] As indicated above the term "oligonucleotide specific for"
or "oligonucleotide targets" refers to an oligonucleotide having a
sequence (i) capable of forming a stable complex with a portion of
the targeted gene, or (ii) capable of forming a stable duplex with
a portion of an mRNA transcript of the targeted gene.
[0223] Selection of appropriate oligonucleotides is facilitated by
using computer programs that automatically align nucleic acid
sequences and indicate regions of identity or homology. Such
programs are used to compare nucleic acid sequences obtained, for
example, by searching databases such as GenBank or by sequencing
PCR products. Comparison of nucleic acid sequences from a range of
species allows the selection of nucleic acid sequences that display
an appropriate degree of identity between species. In the case of
genes that have not been sequenced, Southern blots are performed to
allow a determination of the degree of identity between genes in
target species and other species. By performing Southern blots at
varying degrees of stringency, as is well known in the art, it is
possible to obtain an approximate measure of identity. These
procedures allow the selection of oligonucleotides that exhibit a
high degree of complementarity to target nucleic acid sequences in
a subject to be controlled and a lower degree of complementarity to
corresponding nucleic acid sequences in other species. One skilled
in the art will realize that there is considerable latitude in
selecting appropriate regions of genes for use in the present
invention.
[0224] An antisense compound is "specifically hybridizable" when
binding of the compound to the target nucleic acid interferes with
the normal function of the target nucleic acid to cause a
modulation of function and/or activity, and there is a sufficient
degree of complementarity to avoid non-specific binding of the
antisense compound to non-target nucleic acid sequences under
conditions in which specific binding is desired, i.e., under
physiological conditions in the case of in vivo assays or
therapeutic treatment, and under conditions in which assays are
performed in the case of in vitro assays
[0225] The hybridization properties of the oligonucleotides
described herein can be determined by one or more in vitro assays
as known in the art. For example, the properties of the
oligonucleotides described herein can be obtained by determination
of binding strength between the target natural antisense and a
potential drug molecules using melting curve assay.
[0226] The binding strength between the target natural antisense
and a potential drug molecule (Molecule) can be estimated using any
of the established methods of measuring the strength of
intermolecular interactions, for example, a melting curve
assay.
[0227] Melting curve assay determines the temperature at which a
rapid transition from double-stranded to single-stranded
conformation occurs for the natural antisense/Molecule complex.
This temperature is widely accepted as a reliable measure of the
interaction strength between the two molecules.
[0228] A melting curve assay can be performed using a cDNA copy of
the actual natural antisense RNA molecule or a synthetic DNA or RNA
nucleotide corresponding to the binding site of the Molecule.
Multiple kits containing all necessary reagents to perform this
assay are available (e.g. Applied Biosystems Inc, MeltDoctor kit).
These kits include a suitable buffer solution containing one of the
double strand DNA (dsDNA) binding dyes (such as ABI HRM dyes, SYR
Green, SYTO, etc.). The properties of the dsDNA dyes are such that
they emit almost no fluorescence in free form, but are highly
fluorescent when bound to dsDNA.
[0229] To perform the assay the cDNA or a corresponding
oligonucleotide are mixed with Molecule in concentrations defined
by the particular manufacturer's protocols. The mixture is heated
to 95.degree. C. to dissociate all pre-formed dsDNA complexes, then
slowly cooled to room temperature or other lower temperature
defined by the kit manufacturer to allow the DNA molecules to
anneal. The newly formed complexes are then slowly heated to
95.degree. C. with simultaneous continuous collection of data on
the amount of fluorescence that is produced by the reaction. The
fluorescence intensity is inversely proportional to the amounts of
dsDNA present in the reaction. The data can be collected using a
real time PCR instrument compatible with the kit (e.g.ABI's StepOne
Plus Real Time PCR System or lightTyper instrument, Roche
Diagnostics, Lewes, UK).
[0230] Melting peaks are constructed by plotting the negative
derivative of fluorescence with respect to temperature
(-d(Fluorescence)/dT) on the y-axis) against temperature (x-axis)
using appropriate software (for example lightTyper (Roche) or SDS
Dissociation Curve, ABI). The data is analyzed to identify the
temperature of the rapid transition from dsDNA complex to single
strand molecules. This temperature is called Tm and is directly
proportional to the strength of interaction between the two
molecules. Typically, Tm will exceed 40.degree. C.
Example 2
Modulation of IRS2 and TFE3 polynucleotides Treatment of HepG2
Cells with Antisense Oligonucleotides
[0231] HepG2 cells from ATCC (cat#HB-8065) were grown in growth
media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat
#MT-10-010-CV)+10% FBS (Mediatech cat# MT35-011-CV)+
penicillin/streptomycin (Mediatech cat#MT30-002-CI)) at 37.degree.
C. and 5%, CO2. One day before the experiment the cells were
replaced at the density of 1.5.times.105/ml into 6 well plates and
incubated at 37.degree. C. and 5% CO2. On the day of the experiment
the media in the 6 well plates was changed to fresh growth media.
All antisense oligonucleotides were diluted to the concentration of
20 .mu.M. Two .mu.l of this solution was incubated with 400 .mu.l
of Opti-MEM media (Gibco cat#31985-070) and 4 .mu.l of
Lipofectamine 2000 (Invitrogen cat#11668019) at room temperature
for 20 min and applied to each well of the 6 well plates with HepG2
cells. Similar mixture including 2 .mu.l of water instead of the
oligonucleotide solution was used for the mock-transfected
controls. After 3-18 h of incubation at 37.degree. C. and 5% CO2
the media was changed to fresh growth media. 48 h after addition of
antisense oligonucleotides the media was removed and RNA was
extracted from the cells using SV Total RNA Isolation System from
Promega (cat #Z3105) or RNeasy Total RNA Isolation kit from Qiagen
(cat#74181) following the manufacturers' instructions. 600 ng of
RNA was added to the reverse transcription reaction performed using
Verso cDNA kit from Thermo Scientific (cat#AB1453B) or High
Capacity cDNA Reverse Transcription Kit (cat#4368813) as described
in the manufacturer's protocol. The cDNA from this reverse
transcription reaction was used to monitor gene expression by real
time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and
primers/probes designed by ABI (Applied Biosystems Taqman Gene
Expression Assay: Hs00275843_s1 (IRS2) and Hs00232406_m1 (TFE3) by
Applied Biosystems Inc., Foster City Calif.). The following PCR
cycle was used: 50.degree. C. for 2 mm, 95.degree. C. for 10 min,
40 cycles of (95.degree. C. for 15 seconds, 60.degree. C. for 1
min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).
Fold change in gene expression after treatment with antisense
oligonucleotides was calculated based on the difference in
18S-normalized dCt values between treated and mock-transfected
samples.
Results:
[0232] Real Time PCR results show that levels of IRS2 mRNA in HepG2
cells are significantly increased 48 h after treatment with siRNAs
to TFE3 antisense Hs.708291 (FIG. 1).
[0233] Real Time PCR results show the fold change+standard
deviation in TFE3 mRNA after treatment of HepG2 cells with siRNA
oligonucleotides introduced using Lipofectamine 2000, as compared
to control (FIG. 4).
Treatment of 518A2 Cells with Antisense Oligonucleotides:
[0234] 518A2 cells obtained from Albert Einstein-Montefiore Cancer
Center, NY were grown in growth media (MEM/EBSS (Hyclone cat
#SH30024, Mediatech cat #MT-10-010-CV)+10% FBS (Mediatech
cat#MT35-011-CV)+penicillin/streptomycin (Mediatech
cat#MT30-002-CI)) at 37.degree. C. and 5% CO2. One day before the
experiment the cells were replated at the density of
1.5.times.105/ml into 6 well plates and incubated at 37.degree. C.
and 5% CO2. On the day of the experiment the media in the 6 well
plates was changed to fresh growth media. All antisense
oligonucleotides were diluted to the concentration of 20 .mu.M. Two
.mu.l of this solution was incubated with 400 .mu.l of Opti-MEM
media (Gibco cat#31985-070) and 4 .mu.l of Lipefectamine 2000
(Invitrogen cat#11668019) at room temperature for 20 min and
applied to each well of the 6 well plates with 518A2 cells. Similar
mixture including 2 .mu.l of water instead of the oligonucleotide
solution was used for the mock-transfected controls. After 3-18 h
of incubation at 37.degree. C. and 5%, CO2 the media was changed to
fresh growth media, 48 h after addition of antisense
oligonucleotides the media was removed and RNA was extracted from
the cells using SV Total RNA Isolation System from Promega (cat
#Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat#74181)
following the manufacturers' instructions. 600 ng of RNA was added
to the reverse transcription reaction performed using Verso cDNA
kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA
Reverse Transcription Kit (cat#4368813 as described in the
manufacturer's protocol. The cDNA from this reverse transcription
reaction was used to monitor gene expression by real time PCR using
ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes
designed by ABI (Applied Biosystems Taqman Gene Expression Assay:
Hs00275843_s1 (IRS2) and Hs00232406_m1 (TFE3) by Applied Biosystems
Inc., Foster City Calif.). The following PCR cycle was used:
50.degree. C. for 2 min, 95.degree. C. for 10 min, 40 cycles of
(95.degree. C. for 15 seconds, 60.degree. C. for 1 min) using
StepOne Plus Real Time PCR Machine (Applied Biosystems). Fold
change in gene expression after treatment with antisense
oligonucleotides was calculated based on the difference in
18S-normalized dCt values between treated and mock-transfected
samples.
[0235] Results: Real Time PCR results show that levels of IRS2 mRNA
in 518A2 cells are significantly increased 48 h after treatment
with siRNAs to TFE3 antisense Hs.708291 (FIG. 1).
Treatment Vero76 Cells with Antisense Oligonucleotides:
[0236] Vero76 cells from ATCC (cat#CRL-1587) were grown in growth
media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat
#MT-10-010-CV)+10% FBS (Mediated
cat#MT35-011-CV)+penicillin/streptomycin (Mediatech
cat#MT30-002-CI)) at 37.degree. C. and 5% CO2. One day before the
experiment the cells were replated at the density of
1.5.times.10.sup.5/ml into 6 well plates and incubated at
37.degree. C. and 5% CO2. On the day of the experiment the media in
the 6 well plates was changed to fresh growth media. All antisense
oligonucleotides were diluted in water to the concentration of 20
.mu.M. 2 .mu.l of this solution was incubated with 400 .mu.l of
Opti-MEM media (Gibco cat#31985-070) and 4 ul of Lipofectamine 2000
(Invitrogen cat#11668019) at room temperature for 20 min and
applied to each well of the 6 well plates with Vero76 cells.
Similar mixture including 2 .mu.l of water instead of the
oligonucleotide solution was used for the mock-transfected
controls. After 3-18 h of incubation at 37.degree. C. and 5% CO2
the media was changed to flesh growth media, 48 h after addition of
antisense oligonucleotides the media was removed and RNA was
extracted from the cells using SV Total RNA Isolation System from
Promega (cat #Z3105) or RNeasy Total RNA Isolation kit from Qiagen
(cat#74181), following the manufacturers' instructions. 600 ng of
RNA was added to the reverse transcription reaction performed using
Verso cDNA kit from Thermo Scientific (cat#AB1453B) as described in
the manufacturer's protocol. The cDNA from this reverse
transcription reaction was used to monitor gene expression by real
time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and
primers/probes designed by ABI (Applied Biosystems Taqman Gene
Expression Assay: Hs00275843_s1 (IRS2) and Hs00232406_m1 (TFE3) by
Applied Biosystems Inc., Foster City Calif.). The following PCR
cycle was used: 50.degree. C. for 2 min, 95.degree. C. for 10 min,
40 cycles of (95.degree. C. for 15 seconds, 60.degree. C. for 1
min) using StepOne Plus Real Time PCR Machine (Applied Biosystems).
Fold change in gene expression after treatment with antisense
oligonucleotides was calculated based on the difference in
18S-normalized dCt values between treated and mock-transfected
samples.
[0237] Results: Real Time PCR results show the fold change+standard
deviation in IRS2 mRNA after treatment of Vero76 cells with
phosphorothioate oligonucleotides introduced using Lipofectamine
2000, as compared to control (FIG. 2).
Treatment of MCF-7 Cells with Antisense Oligonucleotides:
[0238] MCF-7 cells from ATC (cat#HTB-22) were grown in growth media
(MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat
#MT-10-010-CV)+10% FBS (Mediatech
cat#MT35-011-CV)+penicillin/streptomycin (Mediatech
cat#MT30-002-CI)) at 37.degree. C. and 5% CO2. One day before the
experiment the cells were replated at the density of
1.5.times.105/ml into 6 well plates and incubated at 37.degree. C.
and 5% CO2. On the day of the experiment the media in the 6 well
plates was changed to fresh growth media. All antisense
oligonucleotides were diluted to the concentration of 20 .mu.M. Two
.mu.l of this solution was incubated with 400 .mu.l of Opti-MEM
media (Gibco cat#31985-070) and 4 .mu.l of Lipofectamine 2000
(Invitrogen cat#11668019) at room temperature for 20 min and
applied to each well of the 6 well plates with MCF-7 cells. Similar
mixture including 2 .mu.l of water instead of the oligonucleotide
solution was used for the mock-transfected controls. After 3-18 h
of incubation at 37.degree. C. and 5% CO2 the media was changed to
fresh growth media. 48 h after addition of antisense
oligonucleotides the media was removed and RNA was extracted from
the cells using SV Total RNA Isolation System from Promega (cat
#Z3105) or RNeasy Total RNA Isolation kit from Qiagen (cat#74181)
following the manufacturers' instructions. 600 ng of RNA was added
to the reverse transcription reaction performed using Verso cDNA
kit from Thermo Scientific (cat#AB1453B) or High Capacity cDNA
Reverse Transcription Kit (cat#4368813) as described in the
manufacturer's protocol. The cDNA from this reverse transcription
reaction was used to monitor gene expression by real time PCR using
ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes
designed by ABI (Applied Biosystems Taqman Gene Expression Assay:
Hs002.75843_s1 (IRS2) and Hs00232406_m1 (TFE3) by Applied
Biosystems Inc., Foster City Calif.). The following PCR cycle was
used: 50.degree. C. for 2 min, 95.degree. C. for 10 min, 40 cycles
of (95.degree. C. for 15 seconds, 60.degree. C. for 1 min) using
StepOne Plus Real Time PCR Machine (Applied Biosystems). Fold
change in gene expression after treatment with antisense
oligonucleotides was calculated based on the difference in
18S-normalized dCt values between treated and mock-transfected
samples.
[0239] Results: Real Time PCR results show the fold change+standard
deviation in IRS2 mRNA after treatment of MCF7 cells with
phosphorothioate oligonucleotides introduced using Lipofectamine
2000, as compared to control (FIG. 3).
[0240] Although the invention has been illustrated and described
with respect to one or more implementations, equivalent alterations
and modifications will occur to others skilled in the art upon the
reading and understanding of this specification and the annexed
drawings. In addition, while a particular feature of the invention
may have been disclosed with respect to only one of several
implementations, such feature may be combined with one or more
other features of the other implementations as may be desired and
advantageous for any given or particular application.
[0241] The Abstract of the disclosure will allow the reader to
quickly ascertain the nature of the technical disclosure. It is
submitted with the understanding that it will not be used to
interpret or limit the scope or meaning of the following claims.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 11 <210> SEQ ID NO 1 <211> LENGTH: 7014
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<300> PUBLICATION INFORMATION: <308> DATABASE ACCESSION
NUMBER: NM_003749 <309> DATABASE ENTRY DATE: 2010-12-25
<313> RELEVANT RESIDUES IN SEQ ID NO: (1)..(7014) <400>
SEQUENCE: 1 cggggaccgc gacgagcccg ggtcgccgtt ggcagcagca gcagcaacac
cagcagcagc 60 agcagccccg gcggcggcgc ggaccccgag cgcccgggcg
caccccggct tcccggagcg 120 cgacgcggcg gcagcagccc cggtgcggcc
gcgcgcgcct taggctcggc cccgcggctc 180 ggggaccccg actcccggcc
cagcgagcgc gtcccccggc gccgcccgag agcccgagga 240 ggcagcggcc
gcaggcagcc ggggaggggg gcggccaccg cccgcgccgg gcatcctcag 300
gagccccaga gcgcggaggg cgcggcgccg ccgagcggtg ctggcccccg cgggcctccc
360 cggaccttcc ccaccgcctg ggcccgaggg acgcgtgatc gggcgggcgg
ccgggcgcaa 420 gggtgggagg gagccgcccc cgcccgcgcc ccctccgccc
ctcgccccaa cccctgggcg 480 ccgggcccgg gccgcgcggc ctgaagcgcc
cgcgatggcg agcccgccgc ggcacgggcc 540 gcccgggccg gcgagcggag
acggccccaa cctcaacaac aacaacaaca acaacaacca 600 cagcgtgcgc
aagtgcggct acctgcgcaa gcagaagcat ggccacaagc gcttcttcgt 660
gctgcgcgga cccggcgcgg gcggcgacga ggcgacggcg ggcggggggt cggcgccgca
720 accgccgcgg ctcgagtact acgagagcga gaaaaagtgg cggagcaagg
caggcgcgcc 780 gaaacgggtg atcgctctcg actgctgcct gaacatcaac
aagcgcgccg acgccaagca 840 caagtacctg atcgccctct acaccaagga
cgagtacttc gccgtggccg ccgagaacga 900 gcaggagcag gagggctggt
accgcgcgct caccgacctg gtcagcgagg gccgcgcggc 960 cgccggagac
gcgccccccg ccgccgcgcc cgccgcgtcc tgcagcgcct ccctgcccgg 1020
cgccctgggc ggctctgccg gcgccgccgg ggccgaggac agctacgggc tggtggctcc
1080 cgccacggcc gcctaccgtg aggtgtggca ggtgaacctg aagcccaagg
gtctgggcca 1140 gagcaagaac ctgacggggg tgtaccgtct gtgcctgtct
gcgcgcacca tcggcttcgt 1200 gaagctcaac tgcgagcagc cgtcggtgac
gctgcagctc atgaacatcc gccgctgcgg 1260 ccactcggac agcttcttct
tcatcgaggt gggccgctcg gccgtcacag gccccggcga 1320 gctgtggatg
caggcggacg actcggtggt ggcgcagaac atccacgaga ccatcctgga 1380
ggccatgaag gcgctcaagg agctcttcga gttccggccg cgcagtaaga gccaatcgtc
1440 ggggtcgtcg gccacgcacc ccatcagcgt ccccggcgcg cgccgccacc
accacctggt 1500 caacctgccc cccagccaga cgggcctggt gcgccgctcg
cgcaccgaca gcctggccgc 1560 caccccgccg gcggccaagt gcagctcgtg
ccgggtgcgc accgccagcg agggcgacgg 1620 cggcgcggcg gcgggagcgg
cggccgcggg cgccaggccg gtgtcggtgg ctgggagccc 1680 cctgagcccc
gggccggtgc gcgcgcccct gagccgctcg cacaccctga gcggcggctg 1740
cggcggccgc gggagcaagg tggcgctgct gccggcaggg ggcgcgctgc aacacagccg
1800 ctccatgtcc atgcccgtgg cgcactcgcc gcccgccgcc accagccccg
gctccctgtc 1860 gtccagcagc ggccacggct cgggctccta cccgccgccg
cccggcccgc acccgcctct 1920 gccgcatccg ctgcaccacg gccccggcca
gcggccctcc agcggcagcg cctccgcctc 1980 gggctccccc agcgaccccg
gcttcatgtc cctggacgag tacggctcca gcccaggcga 2040 cctgcgcgcc
ttctgcagcc accgaagcaa cacgcccgag tccatcgcgg agacgccccc 2100
ggcccgagac ggcggcggcg gcggtgagtt ctacgggtac atgaccatgg acaggcccct
2160 gagccactgt ggccgctcct accgccgggt ctcgggggac gcggcccagg
acctggaccg 2220 agggctgcgc aagaggacct actccctgac cacgccagcc
cggcagcggc cggtgcccca 2280 gccctcctct gcctcgctgg atgaatacac
cctgatgcgg gccaccttct cgggcagcgc 2340 gggccgcctc tgcccgtcct
gccccgcgtc ctctcccaag gtggcctacc acccctaccc 2400 agaggactac
ggagacatcg agatcggctc ccacaggagc tccagcagca acctgggggc 2460
agacgacggc tacatgccca tgacgcccgg cgcggccctc gcgggcagtg ggagcggcag
2520 ctgcaggagc gacgactaca tgcccatgag ccccgccagc gtgtccgccc
ccaagcagat 2580 cttgcagccc agggccgccg ccgccgccgc cgccgccgtg
ccttctgcgg ggcctgcggg 2640 gccagcaccc acctctgcgg cgggcaggac
attcccggcg agcgggggcg gctacaaggc 2700 cagctcgccc gccgagagct
cccccgagga cagtgggtac atgcgcatgt ggtgcggttc 2760 caagctgtcc
atggagcatg cagatggcaa gctgctgccc aacggggact acctcaacgt 2820
gtcccccagc gacgcggtca ccacgggcac cccgcccgac ttcttctccg cagccctgca
2880 ccccggcggg gagccgctca ggggcgttcc cggctgctgc tacagctcct
tgccccgctc 2940 ctacaaggcc ccctacacct gtggcgggga cagcgaccag
tacgtgctca tgagctcccc 3000 cgtggggcgc atcctggagg aggagcgtct
ggagcctcag gccacgccag ggcccagcca 3060 ggcggccagc gccttcgggg
ccggccccac gcagccccct caccctgtag tgccttcgcc 3120 cgtgcggcct
agcggcggcc gcccggaggg cttcttgggc cagcgcggcc gggcggtgag 3180
gcccacgcgc ctgtccctgg aggggctgcc cagcctgccc agcatgcacg agtacccact
3240 gccaccggag cccaagagcc ccggcgagta catcaacatc gactttggcg
agcccggggc 3300 ccgcctgtcg ccgcccgcgc ctcccctgct ggcgtcggcg
gcctcgtcct cctcgctctt 3360 gtccgccagc agcccggcct cgtcgctggg
ctcaggcacc ccgggcacca gcagcgacag 3420 ccggcagcgg tctccgctct
ccgactacat gaacctcgac ttcagctccc ccaagtctcc 3480 taagccgggc
gccccgagcg gccaccccgt gggctccttg gacggcctcc tgtcccccga 3540
ggcctcctcc ccgtatccgc cgttgccccc gcgtccgtcc gcgtccccgt cgtcgtctct
3600 gcagccgccg ccaccgccgc cggccccggg ggagctgtac cgcctgcccc
ccgcctcggc 3660 cgttgccacc gcccagggcc cgggcgccgc ctcatcgttg
tcctcggaca ccggggacaa 3720 tggtgactac accgagatgg cttttggtgt
ggccgccacc ccgccgcaac ctatcgcggc 3780 ccccccgaag ccagaagctg
cccgcgtggc cagcccgacg tcgggcgtga agaggctgag 3840 cctcatggag
caggtgtcgg gagtcgaggc cttcctgcag gccagccagc ccccggaccc 3900
ccaccgcggc gccaaggtca tccgcgcaga cccgcagggg ggccgccgcc gccacagttc
3960 cgagaccttc tcctccacca cgacggtcac ccccgtgtcc ccgtccttcg
cccacaaccc 4020 caagcgccac aactcggcct ccgtggaaaa tgtctctctc
aggaaaagca gcgagggcgg 4080 cgtgggtgtc ggccctggag ggggcgacga
gccgcccacc tccccacgac agttgcagcc 4140 ggcgccccct ttggcaccgc
agggccggcc gtggaccccg ggtcagcccg ggggcttggt 4200 cggttgtcct
gggagcggtg gatcgcccat gcgcagagag acctctgccg gcttccagaa 4260
tggtctcaac tacatcgcca tcgacgtgag ggaggagccc gggctgccac cccagccgca
4320 gccgccgccg ccgccgcttc ctcagccggg agacaagagc tcctggggcc
ggacccgaag 4380 cctcgggggt ctcatcagcg ctgtgggcgt cggcagcacc
ggcggcgggt gcggggggcc 4440 gggtcccggt gccctgcccc ctgccaacac
ctacgccagc attgacttct tgtcccacca 4500 cttgaaggag gccaccatcg
tgaaagagtg aagatctgtc tggctttatc accaggatgt 4560 cacatgtcag
agagtatcat taaaagaaga cgctcagcac tgtttcagcc cgaagctgct 4620
tgcagttttc ttttggatct gagcaatgac tgtgtttgga aacatctgtg gactctgtta
4680 gatgaggcac caacaaggca aggtcacctg cctctttccc ttgttcccgg
atggggcatt 4740 catcattgtg ctgtttgcgt tttgttttgt tttgttttaa
caaaattagc tgaagaagtt 4800 attctcaaga aaattggatg ttttcattgg
ccttcttaaa ttgtggccag tgtcttttaa 4860 tttcttcttc ttttcctttt
ggcaaagcag atataaccct cagcatgcta ggagagtgca 4920 cccgtaccta
tggaagtggt aaaatctggt atttactggc ttacactcaa aacgaccaca 4980
gtcctacctc agttcaaggt aaagccggat ttccgtggcg ggggtcccac aggacctcct
5040 gtagtagccc ctgcgctgtg tgtctggagc gcggtcctcg gccttattga
aatggtccaa 5100 gtagacagct gcttgttgga ttccagtgca ggtacctgcg
atgtttacgt ccacaccgag 5160 cccagtgtgg gactgacatt tctcaatgga
agtgaaattt gggattggac tttgaagacg 5220 gattactaaa taataattat
tatatgtaac tgaagcaacc tacttttgaa aatcaactgt 5280 attgggtagt
gggaggtggg agggaagggc tttgggaagg ggatgaatat ctctttttac 5340
ctttaacaga cttgtttaat cttctcgatg tagatgttta tgtaggtact tcacattgca
5400 aacgcctttt attctattta caagctcaga tgtctctgct ctcctgaatc
ttgggcatgc 5460 ctttctgtaa ccaaaaatcc ctgtaggcgt gctagcaatt
ccagggtggt ccgggtttgg 5520 cagatttgat ttttaaaaaa cgtattatct
ttaataaaat gttattatgt caaccagtga 5580 ggctgccctg aacaaaaaaa
acaaaaagaa aaaaaaaaaa ggaaagaaag aaactgataa 5640 aaagaggcat
tccagcccct atgttattga tggaaaaaga aaaagaagaa aagcaatctc 5700
gcagtacatg ttacttgtcg aaaaaattcc ggacaagact acccttgttt tatgttttca
5760 gtattctgaa aataccagtg tgtggcagtt ctcgcagatg ttacctaaaa
ctgctgaact 5820 tgaccggcag aatgttctgc cgttttctgc tccctcgaca
cttgattgga gggctgtcga 5880 cctctcctcc cgtgggggct tccccagtgc
ctatcttctc tgatagtcat ggagaggtta 5940 cactaattca ttggagatgt
aagttgttgg ttttgttttg ttttgttttt agaaaaatat 6000 atataaatat
ataatagata tctatcgcta tagaataatg cattaataaa atgaggcttt 6060
tttagaggaa gaccaaaaaa ttcaatgtct taaaaatata tttaatggca atgcaaaagt
6120 cttcctgctt ccgtgctgaa ctttagaaca gaggattgta ttgcaagaca
aagttgaatg 6180 taaagtgatc tccctgaaca tttttaaggt tttacttttc
tgaaattata catcacagca 6240 gtgcataggc catataatgt tagctggaag
gtcaatttca gtgtatgata tactttatta 6300 agatgtataa aaatcctgaa
gtttttattt agttttggga ataggcatca atgggtggta 6360 tttgctttgt
aactcccccc aggtacgata gggactgaat atggaccctg ctgaaagcag 6420
tgtattgacg catatttaac tcgccctcta tccgtagagt agtcatgaca ctatacagat
6480 ggttcgtgtt catactgcag cttaaaacaa gcaaaataca cagatgataa
tatgctaaat 6540 tttcctctat cctgtacatt tcacaaaaag gcatatgcaa
tatttacatt tttaatttag 6600 tttacagaat ggaaccaaaa tgtataaatg
ttatgtttgc taaaacttca caatgtatat 6660 tgggtctttg tacattttgc
ctgacttacc ttaaatttaa aatatttttt gctatataaa 6720 ctttaacagt
tattaaacag tgttttcttt ttgggtacgt attgtttctg gatatcaaga 6780
tgttaaatat atttcttgct attgtgatat gacaagagac ttaacttatc ttgctctgtc
6840 ttccactgta cacgctgtat ataggggtca atgtgatgct gctggagacg
agaataaact 6900 ggactagaat agtgcattgt atttagtctg tattgatcat
ggatgccctc cttaatagcc 6960 atatgcaata aaataaagta cattatttat
gaaatgaaaa aaaaaaaaaa aaaa 7014 <210> SEQ ID NO 2 <211>
LENGTH: 497 <212> TYPE: DNA <213> ORGANISM: Homo
sapiens <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (232)..(232) <223> OTHER INFORMATION: n
is a, c, g, or t <220> FEATURE: <221> NAME/KEY:
misc_feature <222> LOCATION: (407)..(407) <223> OTHER
INFORMATION: n is a, c, g, or t <220> FEATURE: <221>
NAME/KEY: misc_feature <222> LOCATION: (482)..(482)
<223> OTHER INFORMATION: n is a, c, g, or t <220>
FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION:
(484)..(484) <223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE: <221> NAME/KEY: misc_feature <222>
LOCATION: (487)..(487) <223> OTHER INFORMATION: n is a, c, g,
or t <400> SEQUENCE: 2 gccaaagtta aaagcgcatc aaacacgcct
agcttttatt attttaatca caaacctata 60 gacccctcag tataccctcc
atggggcctg gccccagcaa tccaaagctg acaaccttgg 120 gtgtaggtat
gaggggtggg aatggagggg ggagtgtctc ttgataactc tgaaatgggg 180
tgattcctcc aaatgaagaa ctgggtgggg aacagaggtt ggggtggcct anattctcag
240 tatgcggagc aataaaaaaa tcagataaac aaatgagggg gtacaatatg
cttttacaac 300 cctcctccaa gcttctgcct tgctggggga aggcttccag
tttttcctgg gctggggagg 360 tcccaggata gccccttcct tcatcctctt
gccctgcact gggcggntcc tttggggaag 420 gtgcagggcc tcatctgact
cctcctcctt gcctgattac aggggtgggg cctgatcaca 480 tntnctnttc ccccagg
497 <210> SEQ ID NO 3 <211> LENGTH: 633 <212>
TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE:
3 tttttttttt ttttttctga aaactgcaaa aggtggcaaa aggtgagaat gggaggagac
60 tcatctgtga ctaactcccc catcagcctc acgggtgggt gacttggagc
tccccaaccc 120 aatgggactt ccttctttcg cctacactgg ccaccaccat
ggagggcagg gaggccaaga 180 gcggcaagca gccctttgag ccggtggggg
ctgtggttgg caggaaagga gggggctttc 240 ctgaacaggc tagggatgcc
tatagaaaga atgtgatcaa tacccttaac gcagcctttg 300 gggctgccta
caaaaaggag ccaagaaacc tgacaatggg gaagtttctg gaatactacc 360
atttacaaca aagactgagc acagaatgaa gtaccaggag agcttggagg caaggccgcc
420 aagagctcag ggcaagctga catctaggaa tcgggatagc agcagaatca
aagctactat 480 ttttcagaga agaaaactta caaacactac ctcatctgat
gcaccccagg ttcacgcagg 540 ggtgaagggg tgaaacatct gagtggtccc
agctgtgaat gggaccagta ctgtgaatgt 600 tccagcaagg atatccactg
ccgccctcgt gcc 633 <210> SEQ ID NO 4 <211> LENGTH: 54
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Antisense
oligonucleotide <400> SEQUENCE: 4 rarurarcrc rurarcrarc
rcrcrararg rgrururgru rcrargrcru ruru 54 <210> SEQ ID NO 5
<211> LENGTH: 54 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Antisense oligonucleotide <400> SEQUENCE: 5
rcrargrcra rargrgrcra rgrarargrc rururgrgra rgrgrargrg rgru 54
<210> SEQ ID NO 6 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide
<400> SEQUENCE: 6 gtctcctccc attctcacct 20 <210> SEQ ID
NO 7 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Antisense oligonucleotide <400> SEQUENCE:
7 cctcctttcc tgccaaccac a 21 <210> SEQ ID NO 8 <211>
LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Antisense oligonucleotide <400> SEQUENCE: 8 gcatccctag
cctgttcag 19 <210> SEQ ID NO 9 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Antisense
oligonucleotide <400> SEQUENCE: 9 tctgctgcta tcccgattcc t 21
<210> SEQ ID NO 10 <211> LENGTH: 48 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Reverse complement of the antisense
oligonucleotide SEQ ID NO: 4 <400> SEQUENCE: 10 rargrcrurg
rarcrararc rcrururgrg rgrurgrura rgrgruat 48 <210> SEQ ID NO
11 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Reverse complement of the antisense
oligonucleotide SEQ ID NO: 5 <400> SEQUENCE: 11 rcrcrurcrc
rurcrcrara rgrcrururc rurgrcrcru rurgrctg 48
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 11 <210>
SEQ ID NO 1 <211> LENGTH: 7014 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <300> PUBLICATION
INFORMATION: <308> DATABASE ACCESSION NUMBER: NM_003749
<309> DATABASE ENTRY DATE: 2010-12-25 <313> RELEVANT
RESIDUES IN SEQ ID NO: (1)..(7014) <400> SEQUENCE: 1
cggggaccgc gacgagcccg ggtcgccgtt ggcagcagca gcagcaacac cagcagcagc
60 agcagccccg gcggcggcgc ggaccccgag cgcccgggcg caccccggct
tcccggagcg 120 cgacgcggcg gcagcagccc cggtgcggcc gcgcgcgcct
taggctcggc cccgcggctc 180 ggggaccccg actcccggcc cagcgagcgc
gtcccccggc gccgcccgag agcccgagga 240 ggcagcggcc gcaggcagcc
ggggaggggg gcggccaccg cccgcgccgg gcatcctcag 300 gagccccaga
gcgcggaggg cgcggcgccg ccgagcggtg ctggcccccg cgggcctccc 360
cggaccttcc ccaccgcctg ggcccgaggg acgcgtgatc gggcgggcgg ccgggcgcaa
420 gggtgggagg gagccgcccc cgcccgcgcc ccctccgccc ctcgccccaa
cccctgggcg 480 ccgggcccgg gccgcgcggc ctgaagcgcc cgcgatggcg
agcccgccgc ggcacgggcc 540 gcccgggccg gcgagcggag acggccccaa
cctcaacaac aacaacaaca acaacaacca 600 cagcgtgcgc aagtgcggct
acctgcgcaa gcagaagcat ggccacaagc gcttcttcgt 660 gctgcgcgga
cccggcgcgg gcggcgacga ggcgacggcg ggcggggggt cggcgccgca 720
accgccgcgg ctcgagtact acgagagcga gaaaaagtgg cggagcaagg caggcgcgcc
780 gaaacgggtg atcgctctcg actgctgcct gaacatcaac aagcgcgccg
acgccaagca 840 caagtacctg atcgccctct acaccaagga cgagtacttc
gccgtggccg ccgagaacga 900 gcaggagcag gagggctggt accgcgcgct
caccgacctg gtcagcgagg gccgcgcggc 960 cgccggagac gcgccccccg
ccgccgcgcc cgccgcgtcc tgcagcgcct ccctgcccgg 1020 cgccctgggc
ggctctgccg gcgccgccgg ggccgaggac agctacgggc tggtggctcc 1080
cgccacggcc gcctaccgtg aggtgtggca ggtgaacctg aagcccaagg gtctgggcca
1140 gagcaagaac ctgacggggg tgtaccgtct gtgcctgtct gcgcgcacca
tcggcttcgt 1200 gaagctcaac tgcgagcagc cgtcggtgac gctgcagctc
atgaacatcc gccgctgcgg 1260 ccactcggac agcttcttct tcatcgaggt
gggccgctcg gccgtcacag gccccggcga 1320 gctgtggatg caggcggacg
actcggtggt ggcgcagaac atccacgaga ccatcctgga 1380 ggccatgaag
gcgctcaagg agctcttcga gttccggccg cgcagtaaga gccaatcgtc 1440
ggggtcgtcg gccacgcacc ccatcagcgt ccccggcgcg cgccgccacc accacctggt
1500 caacctgccc cccagccaga cgggcctggt gcgccgctcg cgcaccgaca
gcctggccgc 1560 caccccgccg gcggccaagt gcagctcgtg ccgggtgcgc
accgccagcg agggcgacgg 1620 cggcgcggcg gcgggagcgg cggccgcggg
cgccaggccg gtgtcggtgg ctgggagccc 1680 cctgagcccc gggccggtgc
gcgcgcccct gagccgctcg cacaccctga gcggcggctg 1740 cggcggccgc
gggagcaagg tggcgctgct gccggcaggg ggcgcgctgc aacacagccg 1800
ctccatgtcc atgcccgtgg cgcactcgcc gcccgccgcc accagccccg gctccctgtc
1860 gtccagcagc ggccacggct cgggctccta cccgccgccg cccggcccgc
acccgcctct 1920 gccgcatccg ctgcaccacg gccccggcca gcggccctcc
agcggcagcg cctccgcctc 1980 gggctccccc agcgaccccg gcttcatgtc
cctggacgag tacggctcca gcccaggcga 2040 cctgcgcgcc ttctgcagcc
accgaagcaa cacgcccgag tccatcgcgg agacgccccc 2100 ggcccgagac
ggcggcggcg gcggtgagtt ctacgggtac atgaccatgg acaggcccct 2160
gagccactgt ggccgctcct accgccgggt ctcgggggac gcggcccagg acctggaccg
2220 agggctgcgc aagaggacct actccctgac cacgccagcc cggcagcggc
cggtgcccca 2280 gccctcctct gcctcgctgg atgaatacac cctgatgcgg
gccaccttct cgggcagcgc 2340 gggccgcctc tgcccgtcct gccccgcgtc
ctctcccaag gtggcctacc acccctaccc 2400 agaggactac ggagacatcg
agatcggctc ccacaggagc tccagcagca acctgggggc 2460 agacgacggc
tacatgccca tgacgcccgg cgcggccctc gcgggcagtg ggagcggcag 2520
ctgcaggagc gacgactaca tgcccatgag ccccgccagc gtgtccgccc ccaagcagat
2580 cttgcagccc agggccgccg ccgccgccgc cgccgccgtg ccttctgcgg
ggcctgcggg 2640 gccagcaccc acctctgcgg cgggcaggac attcccggcg
agcgggggcg gctacaaggc 2700 cagctcgccc gccgagagct cccccgagga
cagtgggtac atgcgcatgt ggtgcggttc 2760 caagctgtcc atggagcatg
cagatggcaa gctgctgccc aacggggact acctcaacgt 2820 gtcccccagc
gacgcggtca ccacgggcac cccgcccgac ttcttctccg cagccctgca 2880
ccccggcggg gagccgctca ggggcgttcc cggctgctgc tacagctcct tgccccgctc
2940 ctacaaggcc ccctacacct gtggcgggga cagcgaccag tacgtgctca
tgagctcccc 3000 cgtggggcgc atcctggagg aggagcgtct ggagcctcag
gccacgccag ggcccagcca 3060 ggcggccagc gccttcgggg ccggccccac
gcagccccct caccctgtag tgccttcgcc 3120 cgtgcggcct agcggcggcc
gcccggaggg cttcttgggc cagcgcggcc gggcggtgag 3180 gcccacgcgc
ctgtccctgg aggggctgcc cagcctgccc agcatgcacg agtacccact 3240
gccaccggag cccaagagcc ccggcgagta catcaacatc gactttggcg agcccggggc
3300 ccgcctgtcg ccgcccgcgc ctcccctgct ggcgtcggcg gcctcgtcct
cctcgctctt 3360 gtccgccagc agcccggcct cgtcgctggg ctcaggcacc
ccgggcacca gcagcgacag 3420 ccggcagcgg tctccgctct ccgactacat
gaacctcgac ttcagctccc ccaagtctcc 3480 taagccgggc gccccgagcg
gccaccccgt gggctccttg gacggcctcc tgtcccccga 3540 ggcctcctcc
ccgtatccgc cgttgccccc gcgtccgtcc gcgtccccgt cgtcgtctct 3600
gcagccgccg ccaccgccgc cggccccggg ggagctgtac cgcctgcccc ccgcctcggc
3660 cgttgccacc gcccagggcc cgggcgccgc ctcatcgttg tcctcggaca
ccggggacaa 3720 tggtgactac accgagatgg cttttggtgt ggccgccacc
ccgccgcaac ctatcgcggc 3780 ccccccgaag ccagaagctg cccgcgtggc
cagcccgacg tcgggcgtga agaggctgag 3840 cctcatggag caggtgtcgg
gagtcgaggc cttcctgcag gccagccagc ccccggaccc 3900 ccaccgcggc
gccaaggtca tccgcgcaga cccgcagggg ggccgccgcc gccacagttc 3960
cgagaccttc tcctccacca cgacggtcac ccccgtgtcc ccgtccttcg cccacaaccc
4020 caagcgccac aactcggcct ccgtggaaaa tgtctctctc aggaaaagca
gcgagggcgg 4080 cgtgggtgtc ggccctggag ggggcgacga gccgcccacc
tccccacgac agttgcagcc 4140 ggcgccccct ttggcaccgc agggccggcc
gtggaccccg ggtcagcccg ggggcttggt 4200 cggttgtcct gggagcggtg
gatcgcccat gcgcagagag acctctgccg gcttccagaa 4260 tggtctcaac
tacatcgcca tcgacgtgag ggaggagccc gggctgccac cccagccgca 4320
gccgccgccg ccgccgcttc ctcagccggg agacaagagc tcctggggcc ggacccgaag
4380 cctcgggggt ctcatcagcg ctgtgggcgt cggcagcacc ggcggcgggt
gcggggggcc 4440 gggtcccggt gccctgcccc ctgccaacac ctacgccagc
attgacttct tgtcccacca 4500 cttgaaggag gccaccatcg tgaaagagtg
aagatctgtc tggctttatc accaggatgt 4560 cacatgtcag agagtatcat
taaaagaaga cgctcagcac tgtttcagcc cgaagctgct 4620 tgcagttttc
ttttggatct gagcaatgac tgtgtttgga aacatctgtg gactctgtta 4680
gatgaggcac caacaaggca aggtcacctg cctctttccc ttgttcccgg atggggcatt
4740 catcattgtg ctgtttgcgt tttgttttgt tttgttttaa caaaattagc
tgaagaagtt 4800 attctcaaga aaattggatg ttttcattgg ccttcttaaa
ttgtggccag tgtcttttaa 4860 tttcttcttc ttttcctttt ggcaaagcag
atataaccct cagcatgcta ggagagtgca 4920 cccgtaccta tggaagtggt
aaaatctggt atttactggc ttacactcaa aacgaccaca 4980 gtcctacctc
agttcaaggt aaagccggat ttccgtggcg ggggtcccac aggacctcct 5040
gtagtagccc ctgcgctgtg tgtctggagc gcggtcctcg gccttattga aatggtccaa
5100 gtagacagct gcttgttgga ttccagtgca ggtacctgcg atgtttacgt
ccacaccgag 5160 cccagtgtgg gactgacatt tctcaatgga agtgaaattt
gggattggac tttgaagacg 5220 gattactaaa taataattat tatatgtaac
tgaagcaacc tacttttgaa aatcaactgt 5280 attgggtagt gggaggtggg
agggaagggc tttgggaagg ggatgaatat ctctttttac 5340 ctttaacaga
cttgtttaat cttctcgatg tagatgttta tgtaggtact tcacattgca 5400
aacgcctttt attctattta caagctcaga tgtctctgct ctcctgaatc ttgggcatgc
5460 ctttctgtaa ccaaaaatcc ctgtaggcgt gctagcaatt ccagggtggt
ccgggtttgg 5520 cagatttgat ttttaaaaaa cgtattatct ttaataaaat
gttattatgt caaccagtga 5580 ggctgccctg aacaaaaaaa acaaaaagaa
aaaaaaaaaa ggaaagaaag aaactgataa 5640 aaagaggcat tccagcccct
atgttattga tggaaaaaga aaaagaagaa aagcaatctc 5700 gcagtacatg
ttacttgtcg aaaaaattcc ggacaagact acccttgttt tatgttttca 5760
gtattctgaa aataccagtg tgtggcagtt ctcgcagatg ttacctaaaa ctgctgaact
5820 tgaccggcag aatgttctgc cgttttctgc tccctcgaca cttgattgga
gggctgtcga 5880 cctctcctcc cgtgggggct tccccagtgc ctatcttctc
tgatagtcat ggagaggtta 5940 cactaattca ttggagatgt aagttgttgg
ttttgttttg ttttgttttt agaaaaatat 6000 atataaatat ataatagata
tctatcgcta tagaataatg cattaataaa atgaggcttt 6060 tttagaggaa
gaccaaaaaa ttcaatgtct taaaaatata tttaatggca atgcaaaagt 6120
cttcctgctt ccgtgctgaa ctttagaaca gaggattgta ttgcaagaca aagttgaatg
6180 taaagtgatc tccctgaaca tttttaaggt tttacttttc tgaaattata
catcacagca 6240 gtgcataggc catataatgt tagctggaag gtcaatttca
gtgtatgata tactttatta 6300 agatgtataa aaatcctgaa gtttttattt
agttttggga ataggcatca atgggtggta 6360 tttgctttgt aactcccccc
aggtacgata gggactgaat atggaccctg ctgaaagcag 6420 tgtattgacg
catatttaac tcgccctcta tccgtagagt agtcatgaca ctatacagat 6480
ggttcgtgtt catactgcag cttaaaacaa gcaaaataca cagatgataa tatgctaaat
6540 tttcctctat cctgtacatt tcacaaaaag gcatatgcaa tatttacatt
tttaatttag 6600 tttacagaat ggaaccaaaa tgtataaatg ttatgtttgc
taaaacttca caatgtatat 6660 tgggtctttg tacattttgc ctgacttacc
ttaaatttaa aatatttttt gctatataaa 6720 ctttaacagt tattaaacag
tgttttcttt ttgggtacgt attgtttctg gatatcaaga 6780 tgttaaatat
atttcttgct attgtgatat gacaagagac ttaacttatc ttgctctgtc 6840
ttccactgta cacgctgtat ataggggtca atgtgatgct gctggagacg agaataaact
6900 ggactagaat agtgcattgt atttagtctg tattgatcat ggatgccctc
cttaatagcc 6960 atatgcaata aaataaagta cattatttat gaaatgaaaa
aaaaaaaaaa aaaa 7014
<210> SEQ ID NO 2 <211> LENGTH: 497 <212> TYPE:
DNA <213> ORGANISM: Homo sapiens <220> FEATURE:
<221> NAME/KEY: misc_feature <222> LOCATION:
(232)..(232) <223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE: <221> NAME/KEY: misc_feature <222>
LOCATION: (407)..(407) <223> OTHER INFORMATION: n is a, c, g,
or t <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (482)..(482) <223> OTHER INFORMATION: n
is a, c, g, or t <220> FEATURE: <221> NAME/KEY:
misc_feature <222> LOCATION: (484)..(484) <223> OTHER
INFORMATION: n is a, c, g, or t <220> FEATURE: <221>
NAME/KEY: misc_feature <222> LOCATION: (487)..(487)
<223> OTHER INFORMATION: n is a, c, g, or t <400>
SEQUENCE: 2 gccaaagtta aaagcgcatc aaacacgcct agcttttatt attttaatca
caaacctata 60 gacccctcag tataccctcc atggggcctg gccccagcaa
tccaaagctg acaaccttgg 120 gtgtaggtat gaggggtggg aatggagggg
ggagtgtctc ttgataactc tgaaatgggg 180 tgattcctcc aaatgaagaa
ctgggtgggg aacagaggtt ggggtggcct anattctcag 240 tatgcggagc
aataaaaaaa tcagataaac aaatgagggg gtacaatatg cttttacaac 300
cctcctccaa gcttctgcct tgctggggga aggcttccag tttttcctgg gctggggagg
360 tcccaggata gccccttcct tcatcctctt gccctgcact gggcggntcc
tttggggaag 420 gtgcagggcc tcatctgact cctcctcctt gcctgattac
aggggtgggg cctgatcaca 480 tntnctnttc ccccagg 497 <210> SEQ ID
NO 3 <211> LENGTH: 633 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 3 tttttttttt
ttttttctga aaactgcaaa aggtggcaaa aggtgagaat gggaggagac 60
tcatctgtga ctaactcccc catcagcctc acgggtgggt gacttggagc tccccaaccc
120 aatgggactt ccttctttcg cctacactgg ccaccaccat ggagggcagg
gaggccaaga 180 gcggcaagca gccctttgag ccggtggggg ctgtggttgg
caggaaagga gggggctttc 240 ctgaacaggc tagggatgcc tatagaaaga
atgtgatcaa tacccttaac gcagcctttg 300 gggctgccta caaaaaggag
ccaagaaacc tgacaatggg gaagtttctg gaatactacc 360 atttacaaca
aagactgagc acagaatgaa gtaccaggag agcttggagg caaggccgcc 420
aagagctcag ggcaagctga catctaggaa tcgggatagc agcagaatca aagctactat
480 ttttcagaga agaaaactta caaacactac ctcatctgat gcaccccagg
ttcacgcagg 540 ggtgaagggg tgaaacatct gagtggtccc agctgtgaat
gggaccagta ctgtgaatgt 600 tccagcaagg atatccactg ccgccctcgt gcc 633
<210> SEQ ID NO 4 <211> LENGTH: 54 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide
<400> SEQUENCE: 4 rarurarcrc rurarcrarc rcrcrararg rgrururgru
rcrargrcru ruru 54 <210> SEQ ID NO 5 <211> LENGTH: 54
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Antisense
oligonucleotide <400> SEQUENCE: 5 rcrargrcra rargrgrcra
rgrarargrc rururgrgra rgrgrargrg rgru 54 <210> SEQ ID NO 6
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Antisense oligonucleotide <400> SEQUENCE: 6
gtctcctccc attctcacct 20 <210> SEQ ID NO 7 <211>
LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Antisense oligonucleotide <400> SEQUENCE: 7 cctcctttcc
tgccaaccac a 21 <210> SEQ ID NO 8 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Antisense
oligonucleotide <400> SEQUENCE: 8 gcatccctag cctgttcag 19
<210> SEQ ID NO 9 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Antisense oligonucleotide
<400> SEQUENCE: 9 tctgctgcta tcccgattcc t 21 <210> SEQ
ID NO 10 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Reverse complement of the antisense
oligonucleotide SEQ ID NO: 4 <400> SEQUENCE: 10 rargrcrurg
rarcrararc rcrururgrg rgrurgrura rgrgruat 48 <210> SEQ ID NO
11 <211> LENGTH: 48 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Reverse complement of the antisense
oligonucleotide SEQ ID NO: 5 <400> SEQUENCE: 11 rcrcrurcrc
rurcrcrara rgrcrururc rurgrcrcru rurgrctg 48
* * * * *